Overview
We are a medical device
company focused on designing, developing and marketing products to treat degenerative conditions of the spine affecting the lumbar
region. We are committed to delivering minimally invasive surgical technologies that enhance patient clinical care while providing
sustained value for our customers. We currently market the AxiaLIF
®
family
of products for single and two level lumbar fusion, the VEO
TM
lateral access and interbody fusion system, the Vectre
™
lumbar posterior fixation system and Bi-Ostetic
TM
bone void filler, a biologics product. Our AxiaLIF products use our
pre-sacral approach, through which a surgeon can access discs in the lumbar region of the spine through an incision adjacent to
the tailbone and perform an interbody fusion procedure through instrumentation that provides direct access to the intervertebral
space. We developed our pre-sacral approach to allow spine surgeons to access and treat intervertebral spaces without compromising
important surrounding soft tissue, nerves
and bone structures
. Our VEO lateral access and
interbody fusion system provides for direct visualization of the psoas muscle and unrestricted lateral fluoroscopic views, which
has allowed us to take market share in the highly competitive lateral fusion segment. We believe that direct visualization allows
a surgeon to have improved visibility of the psoas and the nerves running through this muscle that, when used in conjunction with
neuromonitoring, can potentially reduce complications. We
also market products that may be used
with our AxiaLIF surgical approach, including bowel retractors and additional discectomy tools, as well as a bone graft harvesting
system that can be used to extract bone graft in any procedure for which the use of bone graft is appropriate.
Our philosophy
of continuous improvement is driven by ongoing research and development investment in our core technologies. We support this investment
by diligently expanding, maintaining, and protecting our significant patent portfolio.
From our incorporation
in 2000 through 2004, we devoted substantially all of our resources to research and development and start-up activities, consisting
primarily of product design and development, clinical trials, manufacturing, recruiting qualified personnel and raising capital.
We received 510(k) clearance from the U.S.
Food and Drug Administration, or
FDA, for our
AxiaLIF Legacy product in the fourth quarter of 2004, and commercially introduced our AxiaLIF Legacy product in the United States
in the first quarter of 2005. We received a CE mark to market our AxiaLIF Legacy product in the European market in the first quarter
of 2005 and began commercialization in the first quarter of 2006. We received a CE mark for our AxiaLIF 2L product in the third
quarter of 2006 and began commercialization in the European market in the fourth quarter of 2006. We received FDA 510(k) clearance
for our AxiaLIF 2L product and began marketing this product in the United States in the second quarter of 2008. T
he
AxiaLIF 2L product was discontinued in 2010 after we launched our AxiaLIF Plus 2-Level ™ product in July 2010, for which
we had
received FDA 510(k) clearance in January 2010. We commercially launched our next generation Vectre facet screw system
in April 2010. In the first quarter of 2010, we began distributing Bi-Ostetic bone void filler, a biologics product.
We
commercially launched our AxiaLIF Plus 1-Level product in September 2011, for which we had received FDA 510(k) clearance in March
2011. In 2010, we received 510(k) clearance for our VEO lateral access and interbody fusion system, which was commercially launched
in November 2011, and in July 2012 we received a CE mark for our VEO lateral access and interbody fusion system and
began
commercialization in the European market
.
We currently sell our products through a direct
sales force, independent sales agents and international distributors.
As
of December 31, 2012, over 13,000 fusion procedures have been performed globally using our AxiaLIF products. As of December
31, 2012, we sold our products through 30 direct sales personnel and 33 independent sales agents in the United States and 11 independent
distributors and sales agents internationally. For the year ended December 31, 2012, our revenues were $14.6 million
and our net loss was $29.9 million.
On
March 3, 2013, we entered into an Agreement and Plan of Merger, or the Merger Agreement, with RacerX Acquisition Corp., a wholly-owned
subsidiary of the Company, or Merger Sub, Baxano, Inc., or Baxano, and Sumeet Jain and David Schulte solely as Securityholder Representatives,
or the Securityholder Representatives. Under the terms of the Merger Agreement, we will acquire Baxano through a merger of Merger
Sub with and into Baxano, or the Merger. At the effective time of the Merger, Merger Sub will cease to exist and Baxano will continue
as the surviving corporation and as a wholly-owned subsidiary of the Company.
The dollar value of the shares of our common
stock to be issued in connection with the Merger is expected to be approximately $23.1 million, subject to fluctuations in the
price of our common stock on the NASDAQ Global Market and certain adjustments.
Baxano
is a medical instrument company focused on designing, developing and marketing innovative tools that restore spine function, preserve
healthy tissue, and enable a better quality of life for the patients it serves. Baxano currently markets the patented
iO-Flex® system, a proprietary minimally invasive set of flexible instruments allowing surgeons to target lumbar spinal stenosis
in all three regions of the spine: central canal, lateral recess, and neural foramen, and has developed the patented iO-Tome
TM
instrument to rapidly and precisely remove bone, including the facet joints, which is commonly performed in spinal fusion procedures.
Baxano was founded in 2005 and is headquartered in San Jose, California. The Merger is expected to close early in the second quarter
of 2013 and is subject to TranS1 stockholder approval and customary conditions to closing.
Concurrent
with entering into the Merger Agreement, we entered into a Securities Purchase Agreement, or the Securities Purchase Agreement,
dated March 3, 2013, with certain investors, or the Investors, pursuant to which we will sell to the Investors, and the Investors
will purchase from the Company, an aggregate of 7,543,938 shares of our common stock, at a purchase price of $2.28 per share,
resulting in gross proceeds to the Company of $17.2 million, or the Private Placement Transaction. Consummation of the Private
Placement Transaction is subject to approval by the Company’s stockholders of the issuance of shares of our common stock
in connection with the Merger Agreement and the Securities Purchase Agreement, the closing of the Merger, and other customary
closing conditions set forth in the Securities Purchase Agreement.
Spine Anatomy
The
human spine is the core of the human skeleton and provides important structural support while remaining flexible to allow movement.
It consists of 33 separate interlocking bones called vertebrae that are connected by soft tissue and provide stability while facilitating
motion. Vertebrae are paired into motion segments that move by means of two facet joints and one disc. The facet joints provide
stability and enable the spine to bend and twist while the discs absorb pressures and shocks to the vertebrae. Nerves are contained
in the spinal column and run through the foramen openings to the rest of the body.
The
vertebrae are categorized into five regions: cervical, thoracic, lumbar, sacral and coccyx. The lumbar region, which is at the
bottom of the spine and consists of five vertebrae, is capable of limited movement, and primarily functions as support for the
body’s weight. The sacrum consists of five fused vertebrae labeled S1 through S5 directly below the lumbar region and provide
attachment for the hipbones as well as protection to organs in the pelvic area. The cervical region is the uppermost portion of
the spine (the neck), and consists of seven vertebrae. The thoracic region is the middle portion of the spine below the cervical
spine and above the lumbar spine. This area consists of twelve vertebrae and includes the upper body and ribs. The coccyx, also
known as the tailbone, is at the end of the spine.
Medical Conditions
Affecting the Lumbar Spine and Traditional Treatment Alternatives
Degenerative
conditions of the spine consist of indications such as spondylolisthesis, spinal stenosis and degenerative disc disease and are
common medical conditions affecting the lumbar spine. These degenerative conditions can pinch the spinal canal and the nerves exiting
the spine and result in back pain, leg pain, numbness and loss of motor function. This lower back and leg pain can be overwhelming
for patients as it can have significant physical, psychological and financial implications.
Treatment
alternatives for lumbar spine conditions range from non-operative conservative therapies to highly invasive surgical interventions.
Conservative therapies are typically the initial treatments selected by patients and physicians and they include rest, bracing,
physical therapy, chiropractics, electrical stimulation and medication. When conservative therapies fail to provide adequate pain
relief, surgical interventions, including fusion procedures, may be used to address the pain.
Fusion
procedures attempt to alleviate lower back and leg pain by removing problematic disc material and permanently joining together
two or more opposing vertebrae. This is done in a manner that restores the appropriate space between the vertebrae surrounding
the degenerative disc and eliminates mobility of the affected vertebrae. By restoring disc height and eliminating motion, fusion
attempts to both stabilize the spine and prevent the pinching of the nerves exiting the spine, thereby reducing pain.
Traditional
fusion procedures typically involve an incision in the skin, and cutting muscle or moving organs to gain access to the spine. The
degenerated disc is then removed, a process referred to as a discectomy, and a rigid implant, such as a bone graft or cage, is
inserted to stabilize the diseased vertebrae. This process is referred to as fixation. A combination of the patient’s bone
and/or marrow (bone graft) is usually used to fill the voids in the cage. These materials are intended to promote the growth of
bone between the vertebrae. Surgeons often also affix supplementary rods and screws along the spine to provide additional stabilization
while the vertebrae fuse together during the six to eighteen months following surgery. The primary surgical fusion procedures performed
in the lumbar region include: ALIF, PLIF, TLIF and direct lateral interbody fusion.
Anterior
Lumbar Interbody Fusion, or ALIF.
To perform an ALIF procedure, surgeons access the spine through an incision on
the patient’s abdomen which provides them with direct access to the vertebral space for performing a discectomy and inserting
bone grafts for fusion. Supporting soft tissue and nerves are manipulated or removed to accommodate the anterior access required
by the ALIF procedure. Surgeons commonly perform ALIF procedures in conjunction with a general or vascular surgeon because critical
vasculature and organs must be retracted to gain access to the spine. Complications associated with ALIF procedures include vascular
damage to the vena cava and aorta.
Posterior
Lumbar Interbody Fusion, or PLIF.
To perform a PLIF procedure, surgeons access the spine through an incision on
the center of the patient’s back. The surgeon then navigates through muscles and nerves to gain access to the spine. Once
at the spine, the surgeon removes bone from the lamina to gain access to the affected disc space where a discectomy is performed
and a bone graft is placed. When compared to ALIF procedures, PLIF procedures are generally considered easier to perform and can
achieve better nerve root decompression in certain cases. However, the anatomy of the spine prevents surgeons from removing the
entire degenerated disc and obtaining optimal access for insertion of an implant or bone graft. Complications associated with PLIF
procedures include nerve damage, soft tissue damage and implant migration.
Transforaminal
Lumbar Interbody Fusion, or TLIF.
TLIF procedures are performed in a similar manner to PLIF procedures, except the
surgeon accesses the spine through a small incision slightly to the left or right of the center of the patient’s back. After
reaching the spine, the surgeon removes a portion of the facet joint and navigates through the foramen which provides better visualization
and disc removal capabilities than PLIF. Complications associated with TLIF procedures are similar to those found in PLIF procedures
including nerve damage, soft tissue damage and implant migration.
Direct
Lateral Interbody Fusion.
To perform a direct lateral procedure, the surgeon accesses the spine from the patient’s
side through one or two small incisions. The direct lateral procedure is not appropriate for fusions in the L5/S1 segment because
the pelvis interferes with access. Complications associated with direct lateral procedures are similar to those found in PLIF and
TLIF procedures, including nerve damage and implant migration, and also include bowel injury.
Limitations
of Traditional Lumbar Spine Procedures
While
traditional fusion procedures, such as ALIF, PLIF and TLIF, can be effective at treating medical conditions affecting the lumbar
spine, common drawbacks of these procedures may include:
|
·
|
Disruption to Soft Tissue and Support Structures.
Traditional lumbar fusion procedures require
the creation of a pathway from the skin to the degenerative disc that is large enough to allow direct visualization and work by
the surgeon. It is common to cut through healthy muscle or move critical organs, arteries, nerves and soft tissue, which can lead
to bleeding, scarring, nerve damage and bowel disruption.
|
|
·
|
Significant Blood Loss.
As a result of undergoing current lumbar fusion procedures, patients
typically experience significant blood loss of between 100 and 1,400 cc of blood. As a result, it is common for patients to use
the hospital’s blood supply or donate units of their own blood before a lumbar fusion procedure to replenish any significant
blood loss.
|
|
·
|
Lengthy Operative Procedure Times.
It is common for current lumbar fusion procedures to
take between 90 minutes and 4 hours to complete. With some procedures, a second surgeon may be required. Long procedure times increase
the risks of complications and blood loss. Also, hospital and physician resources are consumed for lengthy periods of time, which
can reduce productivity and increase costs.
|
|
·
|
Lengthy Patient Hospital Stays.
Patients remain in the hospital for an average of three
days following a lumbar fusion procedure.
|
|
·
|
Significant Patient Recovery Time.
Patients typically require three to six months to recover
and rehabilitate after undergoing a lumbar fusion procedure before resuming normal activities.
|
|
·
|
Unresolved Patient Pain.
Patients may continue to experience symptoms after undergoing lumbar
fusion procedures even though x-rays show successful fusion has been achieved through the growth of new bone.
|
Our Solutions
AxiaLIF Products
We
have developed what we believe is a less invasive approach for surgeons to perform fusion surgeries in the L4/L5/S1 region without
many of the drawbacks associated with other lumbar fusion procedures. We refer to this proprietary approach as our pre-sacral approach.
We have developed and are marketing a range of fusion products that are delivered using our pre-sacral approach: AxiaLIF Legacy,
AxiaLIF Plus 1-Level, AxiaLIF Plus 2-Level and AxiaLIF Non-Distracting.
To
access the spine using our pre-sacral approach, the surgeon creates an incision adjacent to the tailbone while the patient is lying
on their stomach. The surgeon then navigates a blunt dissecting tool a short distance along the sacrum using x-ray imaging technologies.
As the dissecting tool is advanced, it moves aside soft tissue structures such as fat and loose connective tissue surrounding the
anterior sacrum. When the tool reaches an access point near the junction of the S1 and S2 vertebral bodies, a guide pin is inserted
through the bone into the disc of the lowest lumbar motion segment (the L5/S1 disc) where the fusion procedure is then performed.
A tubular dissector is inserted over the guide pin to create a tissue-protecting working channel between the surgical access site
and the L5/S1 disc. This protected working channel provides access to the interior of the disc, where rotating cutters, brushes
and rasps are used to remove disc material. This is followed by the introduction of bone graft material with special instrumentation
and finally, insertion of our AxiaLIF implants. The implants immediately provide rigid fixation and can provide restoration of
disc height based on the clinical pathology of the patient. The AxiaLIF Plus 2-Level procedure uses the same approach to provide
access to both the L5/S1 and L4/L5 discs. The AxiaLIF Plus 1-Level and AxiaLIF Plus 2-Level procedures must be supplemented with
facet or pedicle screws, which provide fixation for the back of the spine and are supplied by TranS1.
We
believe our pre-sacral approach and its associated products provide the following benefits for patients, providers and payors:
|
·
|
Less Invasive Approach Minimizes Complications.
Our AxiaLIF products are delivered using
our proprietary pre-sacral approach, which we believe is a less invasive solution for delivering fusion products to the L4/L5/S1
region. Procedures performed utilizing our pre-sacral approach have been documented to have favorable clinical safety profiles
with low complication rates. In a recently published peer reviewed clinical paper, complication rates from procedures utilizing
our pre-sacral approach were shown to be 1.3%. See additional information under the heading “Clinical Experience” below.
The most frequent serious complication reported was bowel injury at 0.6% of cases with no reports in this study of permanent injury.
|
|
·
|
Spinal Stability.
Our approach does not violate or cut through the muscles, ligaments or
bones that control the stability of the spine. Thus, the axial approach to the
spine
does not affect inherent
spinal stability,
a benefit that
cannot be achieved with other approaches to interbody fusion. Moreover, in another recent peer-reviewed retrospective clinical
series, the fusion rate associated with procedures utilizing our pre-sacral approach was demonstrated to be 94%. We believe this
compares favorably with the fusion rates of 90-95% associated with other fusion procedures. See additional information under the
heading “Clinical Experience” below.
|
|
·
|
Cost Effectiveness.
Increased focus on health care quality and value has brought greater scrutiny than ever on the clinical
and economic impact that technologies have on different stakeholders including patient, provider and payor. Various government
and commercial programs, including payment bundling, accountable care organizations and value-based purchasing, now incentivize
providers to deliver quality care in a cost-effective manner. We believe that pre-sacral interbody fusion employing our AxiaLIF
device is well positioned in the current health economic climate based on its evidence of good clinical outcomes combined with
a favorable economic profile. In addition to low morbidity, there are procedural efficiencies associated with pre-sacral interbody
fusion that can potentially reduce costs borne by the provider and/or payor. A recently submitted analysis by a leading university
researcher estimated a cost savings of approximately $4,500 associated with the pre-sacral interbody fusion procedure's short length
of stay and reduced complication rate compared to traditional lumbar fusion procedures. Traditionally, surgeon-decision makers
weighted a technology's clinical profile more heavily than hospital economic considerations; however with the rapid growth in surgeons
seeking employment by hospitals, we believe that economics will be a more important driver of medical technology adoption going
forward. We believe that this will provide an opportunity for us to differentiate AxiaLIF from the traditional approaches to lumbar
interbody fusion based on quality outcomes combined with positive impact on payor and provider economics.
|
VEO Lateral
Access and Interbody Fusion System
Our
VEO Lateral Access and Interbody Fusion System provides for direct visualization during lateral fusion surgery and is indicated
for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one or two contiguous levels from
L2-S1. Through a combination of direct visualization of the psoas muscle and unrestricted lateral fluoroscopic views, the VEO Lateral
System offers visualization of the operative site. The VEO direct visualization approach was designed to help minimize iatrogenic
trauma to the psoas muscle and the nerve plexus to help reduce the risk of post-operative complications.
Our
VEO Lateral System includes a radiolucent tubular retractor that was designed to prevent soft tissue intrusion. It facilitates
the first of two retraction stages, providing direct visualization of the psoas muscle and associated nerves
before
dissection of the psoas muscle. This intermediary step allows the surgeon to augment neuromonitoring information with direct visualization
and was designed to help avoid the nerves when dissecting through the psoas muscle to the operative site.
The
VEO’s retractor system features controlled retraction in the anterior/posterior plane via a muscle-splitting and muscle-sparing
approach. The retractor system may reduce muscle disruption and is designed to eliminate the migration of muscle into the surgeon’s
working area. The VEO Lateral System offers a comprehensive portfolio of interbody implants in both parallel and lordotic angles
to better match each patient’s anatomy. The VEO PEEK interbody implants contain 5 tantalum markers to enable fluoroscopic
visualization of placement.
The
VEO Lateral System provides a complete discectomy and endplate preparation instrument set. Designed specifically for a lateral
approach, these instruments are dimensionally optimized for operative visualization and controlled surgical manipulations.
Our Strategy
Our
goal is to become a global leader in minimally invasive treatments for conditions affecting the lumbar region of the spine. To
achieve this goal, we are pursuing the following strategies:
|
·
|
Establish our Pre-Sacral Approach as a Standard of Care for Lumbar Spine Surgery.
We believe
patients commonly avoid spine fusion surgery due to its invasive nature and other drawbacks associated with other surgical treatment
options. We expend significant resources promoting our pre-sacral approach as a less invasive approach to back fusion surgery,
and we believe the advantages of our technique will enable our AxiaLIF products to become a standard of care for the lumbar region
of the spine. We also make substantial research and development expenditures to enhance our AxiaLIF products and develop new products
to expand our technological advantage in minimally invasive spine surgeries.
|
|
·
|
Drive Reimbursement for the AxiaLIF Procedure.
As a result of our efforts over the past
two years, a new Category I Medicare reimbursement code was established on January 1, 2013 for pre-sacral access that is applicable
for our AxiaLIF procedures. We have also demonstrated success in obtaining reimbursement coverage from private insurance companies
through our advocacy efforts. We plan to continue to work with our surgeon customers to generate published, peer reviewed clinical
literature that demonstrates our AxiaLIF procedure’s clinical efficacy and safety. The clinical papers discussed below under
the heading “Clinical Experience” are examples of our continued efforts towards the execution of this strategy. Working
with surgeons that perform AxiaLIF procedures, we will continue our effort to leverage this data with payors to secure positive
coverage decisions for the surgeon reimbursement portion of the AxiaLIF procedure (hospital reimbursement for AxiaLIF already exists).
|
|
·
|
Focus our Sales and Marketing Infrastructure to Drive Surgeon Adoption of our Products.
We intend to continue expending significant resources targeting spine surgeons through our sales and marketing efforts in the United
States and internationally in order to drive the adoption of our pre-sacral and direct lateral approaches.
|
|
·
|
Opportunistically Pursue Acquisitions of Complementary Businesses and Technologies.
In addition
to building our internal product development efforts, we intend to selectively license or acquire complementary products and technologies
that we believe will enable us to leverage our focus on minimally invasive spine products and our sales and marketing infrastructure.
|
|
·
|
Expand Our Presence in the Direct Lateral Interbody Fusion Market.
We intend to support
the growing adoption of our VEO Lateral System through focused surgeon training programs, expanded sales representative training
and marketing promotion.
|
Clinical Experience
As of the date of
this annual report, over 13,000 procedures have been performed using our pre-sacral approach by more than 500 surgeons. This amount
includes over 11,000 procedures using AxiaLIF Legacy or AxiaLIF Plus 1-Level,
with
the remainder being implants
using AxiaLIF 2L or AxiaLIF Plus 2-Level. Our AxiaLIF Legacy and AxiaLIF Plus 1-Level products
have been the subject of a significant number of clinical evaluations and medical publications. We believe that more than 69 articles
have now been published about the clinical experience associated with utilizing our AxiaLIF products. The results of three published
articles are summarized below:
|
·
|
In September 2011, an article was published
in the
SAS Journal
(“Complications with Axial Presacral Lumbar Interbody Fusion: A Five-Year Postmarket Surveillance
Experience,” Gundanna, et al) that discusses the outcome of a retrospective clinical study involving 9,152 patients that
had previously undergone procedures using our pre-sacral approach. The publication demonstrated that the complication rate arising
from lower lumbar fusion utilizing our pre-sacral approach was approximately 1.3%. This complication rate characterizes early onset
complications, and does not include cases of revision or re-operations that may occur months or years later. Reflective of a greater
than 90% published fusion rate for AxiaLIF, the overall complications are quite low in comparison to traditional interbody fusions
such as ALIF or TLIF, which are in the 5% to well over 15% range in published literature. The most frequent serious complication
reported was bowel injury at 0.6% of cases with no reports in this study of permanent injury.
|
|
·
|
In September 2011, a separate article was published in Spine (“Minimally-invasive Axial Pre-sacral
L5-S1 Interbody Fusion: Two Year Clinical and Radiographic Outcomes,” Tobler, et al) that discusses the outcome of a retrospective
clinical series involving 156 patients in four separate medical centers. The publication demonstrated an approximately 63% improvement
in patient pain two years after surgery compared to immediately prior to the procedure. In addition, the article discusses that,
two years after surgery in patients receiving a fusion procedure utilizing our pre-sacral approach, there was a 54% improvement
in the Oswestry Disability Index, or ODI, a commonly used measure for levels of disability in daily living activities. The article
also reports that the procedures utilizing our pre-sacral approach demonstrated a 94% fusion rate. We believe this rate compares
favorably with the fusion rates of 90-95% associated with other fusion procedures as reported in other studies. The article further
concludes that, for the evaluated population, our pre-sacral approach did not result in any vascular or neural injury. In addition,
while we have received reports of bowel injury associated with our pre-sacral approach, no bowel injuries were reported in this
article. Not all patients have the same experience when treated with AxiaLIF.
|
|
·
|
In April 2012, an article was published in the
Journal of Spinal Disorders and Techniques
(“Axial Presacral Lumbar Interbody Fusion and Percutaneous Posterior Fixation for Stabilization of Lumbosacral Isthmic Spondylolisthesis,”
Gerszten, et al) that discusses the outcome of a retrospective case series of 26 patients with Grade 1 or 2 spondylolisthesis.
The publication demonstrated a 66% improvement in pain at 2 years post-surgery compared to baseline. Additionally, patients reported
81% excellent/good results based on the Odom’s criteria. The Odom’s criteria is a subjective scale that rates patient
outcomes as excellent, good, fair or poor. Lastly, the publication reported a solid fusion rate of 100% for all patients at 2 years
post-surgery. The article concludes that the pr
esacral
axial interbody fusion and posterior instrumentation technique is a safe and effective treatment for low-grade isthmic spondylolisthesis.
|
A literature review
is a critical and in-depth evaluation of previous research. In 2011 and 2012 there were two such publications that reviewed the
clinical safety and effectiveness of the AxiaLIF system. Additionally, a third review article (which has been submitted for publication)
focuses on the health economics of the AxiaLIF system compared to TLIF. These reviews are outlined below:
|
•
|
In August 2011 Rapp, et al in
Medical Devices: Evidence and Research
(“AxiaLIF System:
minimally invasive device for presacral lumbar interbody spinal fusion”) reviewed AxiaLIF data from three separate sites.
In his review of 120 patients, there was a reported complication rate of 0-3%, which is comparable to the Gundanna paper (“Complications
with Axial Presacral Lumbar Interbody Fusion: A Five-Year Postmarket Surveillance Experience,”
SAS Journal
, Sept 2011)
that reported a complication rate of 1.3% in 9,152 patients. Rapp et al also reported fusion rates of 85-93%. These are comparable
to Durrani, et al in
Techniques in
Orthopaedics
(“Presacral Approach for L5-S1 Fusion,” 2011) who noted
an overall fusion rate of 88-94% in his review.
|
|
•
|
In regards to clinical effectiveness, Durrani’s literature review (
Techniques in Orthopaedics
)
demonstrated significant improvements in pre-operative pain and function levels compared to post-operative levels. The Visual Analog
Scale, or VAS, used to denote patient pain, showed a 41-63% reduction in pain post-operatively, and ODI scores, used to calculate
a patient’s functional status, improved overall by 50-54%..
|
|
•
|
In 2012, a systematic literature review was performed on the health economics of the AxaiLIF system. The
findings showed that the axial pre-sacral approach was associated with decreases in blood loss, operative times, length of hospital
stay, and resulted in reduced surgical morbidity, all of which are factors that drive healthcare costs. These findings are mirrored
in the review conducted by Durrani, et al. Cost estimation suggests that these benefits of minimally invasive fusion can be expected
to result in significant cost savings for hospitals and payors. An estimated realization of cost savings averaged approximately
$4,500 per patient over open TLIF for single-level fusion for degenerative spine disease. This paper has been submitted to
World
Neurosurgery
.
|
In August 2012, we
completed our first retrospective clinical study comparing AxiaLIF to ALIF. The primary objective of the study was to compare
fusion rates and reported complication between the two procedures. There were 48 subjects in each cohort with a minimum of two-year
follow-up. The overall fusion was 85% in the AxiaLIF cohort compared to 79% within the ALIF cohort. The complication rate was
higher in the ALIF group, who additionally reported one serious adverse event that necessitated significant fluid resuscitation.
This paper has been accepted for publication by
The Journal of Spinal Disorders and Techniques
and has been accepted for
a podium presentation at the North American Spine Society Summer Meeting in July 2013.
Our Products
We currently market
the AxiaLIF family of products for single and two level lumbar fusion, the VEO lateral access and interbody fusion system, the
Vectre posterior fixation system and Bi-Ostetic bone void filler, a biologics product. We
also
market products that may be used with our AxiaLIF surgical approach, including bowel retractors and additional discectomy tools,
as well as a bone graft harvesting system that can be used to extract bone graft in any procedure for which the use of bone graft
is appropriate.
|
·
|
AxiaLIF Lumbar Fusion Implants.
Our AxiaLIF products include surgical instruments
designed to create a safe and reproducible access route to the L4/L5/S1 vertebral bodies, fusion implants and supplemental stabilization
products. We believe our AxiaLIF implants and instruments, combined with facet screws or pedicle screws, provide surgeons with
the tools necessary to perform a lumbar fusion in a less invasive manner. We sell these products to our customers in procedure
kits that include all the instruments and implants needed to complete a lumbar fusion.
|
Our
AxiaLIF Plus 1-Level, 2-Level and Non-Distracting implants are threaded titanium anchors, that come in varying lengths to enable
one-level L5/S1 fusions and two-level L4/L5/S1 fusions. As they are implanted, our proprietary design can allow for the
separation or distraction of the vertebrae to restore disc height based on the clinical pathology of the patient. The increased
disc height relieves pressure on the nerve, while the rod itself provides immediate rigid fixation.
Our
pre-sacral approach requires the use of a sterile set of surgical instruments that are used to create a working channel and to
prepare the disc and vertebrae for our implant. The instrumentation contained in the set includes stainless steel navigation tools
and tubular dissectors to create the working channel, as well as nitinol cutters and brushes to cut and remove the degenerated
disc material and prepare the disc space for our implant and the bone graft material.
|
·
|
VEO Lateral Access and Interbody Fusion System.
In November 2011, we launched our VEO Lateral Access and Interbody Fusion System. This minimally invasive direct lateral system
features a two-stage retraction method that focuses on nerve visualization followed by muscle retraction. The VEO Lateral System
is designed for direct visualization of the psoas muscles and adjacent nerves prior to muscle dissection, and features a full range
of PEEK lateral interbody implants and a variety of ergonomic instruments.
|
|
·
|
Vectre Facet Screw System.
Our Vectre facet screw system offers a cannulated
facet screw inserted over a guidewire to provide stability. The Vectre system features are designed to offer a minimally invasive
posterior fixation option in select patients.
|
|
·
|
Bi-Ostetic Bone Void Filler.
In February 2010, we began selling Bi-Ostetic, a synthetic,
osteoconductive material intended to be used to fill voids and gaps that are not intrinsic to the stability of bone structure.
These gaps or voids may be located in the extremities, spine, or pelvis. In spine surgery, it can be used to fill a void in the
sacrum or as a substitute or adjunct to autograft or allograft during posterolateral fusion. Bi-ostetic is not indicated for use
in the interbody space during interbody fusion procedures or in load bearing applications.
|
|
·
|
Iliac Crest Bone Graft Harvesting System.
Our Iliac Crest Bone Graft Harvesting System was
developed to aid surgeons in harvesting iliac crest autograft via a minimally invasive approach. Fusion success is dependent on
a proper disc preparation technique, including a thorough discectomy with removal of the cartilaginous endplate and nuclear material.
Use of autograft, which is osteogenic, osteoinductive and osteoconductive, further improves the chances of fusion success. Because
it is harvested from the patient, it eliminates risk of disease transmission. It provides structural support as well as scaffolding
for new bone growth.
|
Product Pipeline
Our product development
efforts are currently focused on pursuing improvements to enhance our current product lines and to also pursue products that have
a short pathway to regulatory clearance and commercialization. We are developing a minimally invasive pedicle screw system that
will deliver a simple, complete solution for posterior fixation in the lumbar spine. In 2012, we received FDA 510(k) clearance
for a TLIF cage system that we plan to develop in the next two years.
In
the future, we expect our product offerings will be expanded to address additional clinical applications in the surgical treatment
of conditions affecting the lumbar spine with an emphasis on minimally invasive approaches. Such applications could require FDA 510(k)
clearance or premarket approval, or PMA, most likely supported by safety and efficacy data from clinical trials. We also have an
active program aimed at developing tools that will improve outcomes and lower complications for our procedures.
Market Opportunity
Our
management believes that approximately 240,000 lumbar spinal fusion procedures will be performed in the United States in 2013,
of which approximately 190,000, or 79%, are applicable to our AxiaLIF and/or VEO systems. Based on our current product offerings
and mix, this represents a $2.5 billion addressable market. With the addition of our planned pedicle screw system, and further
penetration of our ancillary products, such as bone void filler and bone graft harvestors, the potential market exceeds $4 billion.
Sales and Marketing
Our
sales and marketing effort primarily targets spine surgeons. We also market our products at various industry conferences and through
industry organized surgical training courses.
In the United States,
we market and sell our products through a combination of direct sales representatives and independent sales agents. As of December
31, 2012, our U.S. sales team included area vice-presidents, regional managers, direct sales representatives, case coverage
specialists and independent sales agents covering specific geographic regions. Our sales representatives receive a base salary
and a percentage of the net sales that they generate. As of December 31, 2012, we had 26 direct sales representatives, one case
coverage specialist, three regional managers and two area vice-presidents. The independent sales agents are compensated based on
a percentage of the net sales that they generate. We have agreements with our independent sales agents that provide them with an
exclusive right to sell our products in their territories, which are generally terminable upon 90 days’ written notice.
Outside
of the United States, we utilize independent sales distributors and sales agents. Through December 31, 2012, the majority of our
international sales have been to distributors in Europe. In 2008, we hired direct sales representatives in Germany, and in 2009
we began direct sales through our own sales representatives and agents in Germany, Switzerland, Netherlands and Belgium. Effective
January 1, 2012, we replaced our direct sales representatives in Europe with an independent sales agent, comprised of former employees
of our direct sales organization, representing Germany, Netherlands, and Belgium. In January 2013, we terminated this sales agent
and are transitioning to other distribution channels in these regions. In October 2012, we signed an agreement with Jiade Sunshine
to distribute our products in China, and we recorded $1.0 million of revenue in the fourth quarter of 2012 for sales to this distributor.
In 2012, 80% of our international revenues were through third-party distributors and 20% were through independent sales agents.
In
2012, no customer accounted for 10% or more of revenues.
Surgeon Training
We
devote significant resources to training and educating surgeons on the specialized skills involved in the proper use of our instruments
and implants. We believe that the most effective way to introduce and build market demand for our products is by training spine
surgeons in the use of our products. We accomplish our training objectives primarily through cadaver and surrogate models and live
case observations with surgeons experienced in our pre-sacral approach. We supplement this training with online didactic tutorials.
After this training, surgeons are generally able to perform unsupervised surgeries using our pre-sacral approach. As of December
31, 2012, we had trained over 1,500 U.S. spine surgeons and over 300 surgeons outside of the U.S. in the use of our single-level
product. In addition, we have trained over 500 U.S. spine surgeons in the use of our AxiaLIF Plus 2-Level and 2L products. Of the
U.S. surgeons trained on our pre-sacral approach, approximately 130 have performed a procedure in the 12 months ended December
31, 2012. Through December 31, 2012, we have also trained over 190 U.S. spine surgeons in our VEO lateral access and interbody
fusion system and 20 surgeons outside the U.S. Of the U.S. surgeons trained on our VEO lateral access and interbody fusion system,
approximately 50 have performed a procedure in the 12 months ended December 31, 2012. We believe we have the necessary capacity
to train a sufficient number of surgeons to meet our current goals.
In
February 2012, we opened a training facility in Raleigh, N.C., which has a state-of-the art operating room unit with a fully equipped
surgical suite. The facility provides cadaveric capabilities to allow hands-on training for spine surgeons and our staff.
Third-Party
Reimbursement
In
the United States, healthcare providers generally rely on third-party payors, principally private insurers and governmental payors
such as Medicare and Medicaid, to cover and reimburse all or part of the cost of a spine fusion surgery in which our medical device
is used. Surgeons are reimbursed for performing the surgical procedure, while hospitals are reimbursed for the cost of the device,
all patient care related to the fusion procedure and the overhead associated with maintaining the facility.
Most
payors follow Medicare's Diagnosis-Related Group, or DRG, based payment system for reimbursing facilities. Under this model, hospitals
are paid a set amount to cover the costs associated with a fusion patient, including the cost of the device used in the procedure.
The most commonly associated DRGs for spinal fusion are 453/454/455 (“Combined Anterior/Posterior Spinal Fusion with major
complications and comorbidities (MCC), with complications and comorbidities (CC) or without MCC/CC”) and 459/460 (“Spinal
Fusion Except Cervical with or without MCC”). Private payors typically use Medicare DRGs as a benchmark when setting their
own reimbursement rates for facilities but typically pay above Medicare established rates.
Surgeons use the American
Medical Association’s, or the AMA’s, Current Procedural Terminology, or CPT, system to bill payors for their service
in performing the AxiaLIF and VEO procedures. CPT codes describe the services and procedures provided for patients to third-party
payors so that physicians may be reimbursed. For CPT coding purposes, our VEO procedure is considered an anterior lumbar interbody
fusion, for which a Category I code has existed for some time. Effective January 1, 2009, the AMA implemented a Category III code
which describes the work involved in treating AxiaLIF patients. Unlike Category I CPT codes, Category III codes do not have a set
value which physicians use as a benchmark for setting their fee. Additionally, some payors view Category III codes as “investigational”
or “experimental” and may not reimburse them. However, unlike many new or novel procedures, AxiaLIF is an access variation
on the current standard of care (interbody spinal fusion) and has been performed in over 13,000 U.S. procedures. The implementation
of a Category III code for our AxiaLIF products, together with a broad reduction in payor approval for spinal fusion procedures
beginning in 2009, resulted in a period of persistent decline in our revenues. With the establishment of a Category I code effective
January 1, 2013, we believe that we are in a position to transition to a period of sustainable revenue growth.
In March 2012, we
announced that the Current Procedural Terminology Editorial Panel, or the Panel, voted to approve an application for a new Category
I CPT code, 22586, for L5/S1 spinal fusion utilizing our AxiaLIF implant when performing a pre-sacral interbody fusion. In addition,
the Panel voted to establish a new Category III CPT code, 0309T, as an add-on code to the new Category I code for use with 22586
when performing L4/5 spinal fusion. The new CPT codes were announced on the AMA’s website on March 2, 2012, and became effective
on January 1, 2013. The Medicare final rule was released in November 2012, which stated a
valuation of the Category I CPT code 22586 for pre-sacral interbody single level spinal fusion at L5-S1, and
became effective
January 1, 2013. This
CPT code, which applies to our AxiaLIF Plus 1-Level
device, is a bundled lumbar arthrodesis procedure that includes bone graft, posterior instrumentation and fixation.
Internationally,
reimbursement and healthcare payment systems vary substantially from country to country and include single-payor, government-managed
systems as well as systems in which private payors and government-managed systems exist side-by-side. Our ability to achieve market
acceptance or significant sales volume in international markets we enter will depend in large part on the availability of reimbursement
for procedures performed using our products under the healthcare payment systems in such markets. There is favorable reimbursement
in Germany for the AxiaLIF Legacy procedure. We also received a favorable ruling from the British United Provident Association,
the leading provider of private health insurance and healthcare services in the United Kingdom. A small number of countries may
require us to gather additional clinical data before recognizing coverage and reimbursement for our products. It is our intent
to complete the requisite clinical studies and obtain coverage and reimbursement approval in countries where it makes economic
and strategic sense to do so.
We
believe that the overall escalating cost of medical products and services has led to, and will continue to lead to, increased pressures
on the healthcare industry to reduce the costs of products and services. We cannot assure you that government or other third-party
payors will cover and reimburse our procedures in whole or in part in the future or that payment rates will be adequate. In addition,
it is possible that future legislation, regulation, or reimbursement policies of third-party payors will adversely affect the demand
for our procedures and products or our ability to sell them on a profitable basis. The unavailability or inadequacy of third-party
payor coverage or reimbursement could have a material adverse effect on our business, operating results and financial condition.
Competition
The
medical device industry is highly competitive, subject to rapid technological change and significantly affected by new product
introductions and market activities of other participants. Our currently marketed products are, and any future products we commercialize
will be, subject to intense competition. Our competitors include providers of conservative, non-operative therapies for lower lumbar
spine conditions, as well as a number of major medical device companies that have developed or plan to develop products for minimally
invasive spine surgery in each of our current and future product categories. We believe that the principal competitive factors
in our markets include:
|
·
|
improved outcomes for medical conditions affecting the lumbar spine;
|
|
·
|
acceptance by spine surgeons;
|
|
·
|
ease of use and reliability;
|
|
·
|
product price and qualification for reimbursement;
|
|
·
|
technical leadership and superiority;
|
|
·
|
effective marketing and distribution; and
|
We
are aware of several companies that compete or are developing technologies in our current and future product areas. As a result,
we expect competition to remain intense. Our most significant competitors are Medtronic Sofamor Danek, Johnson & Johnson
DePuy Spine, Stryker Spine, NuVasive, Zimmer Spine, Synthes, Orthofix International, Globus Medical and Alphatec Spine, many of
which have substantially greater sales and financial resources than we do. In addition, these companies may have more established
distribution networks, entrenched relationships with physicians, and greater experience in launching, marketing, distributing and
selling products.
Additional competition
also comes from physician-owned spine specific medical device distribution companies, which have expanded in recent years. These
companies, which are partially owned or completely owned by spine surgeons, have significant market knowledge and access to the
physicians who use our products and the hospitals that purchase our products. These surgeons may have an incentive to direct implant
use toward implants that are distributed by these organizations.
Our
ability to compete successfully will depend on our ability to develop proprietary products that reach the market in a timely manner,
receive adequate reimbursement and demonstrate that they are safer and less invasive than alternatives available for the same purpose.
Because of the size of the potential market, we anticipate that companies will dedicate significant resources to developing competing
products.
Research and
Development
As
of December 31, 2012, our research and development team was comprised of 11 employees who have extensive experience in developing
products to treat medical conditions affecting the lumbar spine. These employees work closely with our clinical advisors and spine
surgeon customers to design and enhance our products and approach. Our research and development spending was $5.5 million, $5.2
million and $4.2 million for the years ending December 31, 2012, 2011 and 2010, respectively. Since inception, we have devoted
significant resources to develop and enhance our products
and expect to continue to do so in the
future.
Manufacturing
and Supply
We
rely on third parties to manufacture all of our products and their components, except for our nitinol nucleus cutter blades, which
we manufacture at our facility in Wilmington, North Carolina. Our outsourcing partners are manufacturers that meet FDA, International
Organization for Standardization, or ISO, and other internal quality standards, where applicable. We believe these manufacturing
relationships allow us to work with suppliers who have the best specific competencies while we minimize our capital investment,
control costs and shorten cycle times, all of which we believe allows us to compete with larger-volume manufacturers of spine surgery
products.
All
of our products and components are assembled, packaged, labeled and sterilized, if applicable, at third-party facilities in the
United States under our existing contracts requiring compliance with Good Manufacturing Processes, or GMPs. Following receipt of
products or components from our third-party manufacturers, we inspect, warehouse and ship the products and components at our facilities
in Wilmington or at a third-party distribution facility in Memphis, Tennessee. We reserve the exclusive right to inspect and assure
conformance of each product and component to our specifications. In addition, FDA or other regulatory authorities may inspect our
facilities and those of our suppliers to ensure compliance with Quality System Regulations, or QSR.
The
majority of our instruments and implants are produced by third-party manufacturers on precision, high-speed machine shop equipment.
However, for a certain number of our products, the components and materials used to manufacture such products and the manufacturing
operations are performed or supplied by third-party specialty vendors due to their proprietary or non-conventional nature. For
example, the blades for our nucleus cutters are made from a metal called nitinol, which is converted into strip form by three manufacturers
in the United States known to us. We have sourced nitinol strip from two of these vendors. The nitinol strip is then further converted
for us into cutter blanks by a scalpel blade specialty vendor. Other vendors are available to manufacture the cutter blanks, as
we may deem desirable or necessary. We convert the cutter blanks into cutter blades at our facilities. Our tissue extractor product
is produced for us by a supplier that specializes in wire forming and coiling specifically for the medical device industry. A limited
number of similar vendors exist that could be used to produce the tissue extractor product, and we believe we could replace this
supplier on reasonable terms without substantial delay, if necessary.
We
are currently working with our third-party manufacturers to plan for our future manufacturing requirements. In most cases, we have
redundant manufacturing capability with multiple vendors and enjoy the significant capacity this arrangement provides to us. We
may consider manufacturing certain products or product components internally, if and when demand or quality requirements make it
appropriate to do so. We believe the manufacturing capacity available to us is sufficient to meet our demands into the foreseeable
future.
Patents and
Proprietary Technology
We
rely on a combination of patent, trademark, copyright, trade secret and other intellectual property laws, nondisclosure agreements
and other measures to protect our intellectual property rights. We believe that in order to have a competitive advantage, we must
develop and maintain the proprietary aspects of our technologies. We require our employees, consultants and advisors to execute
confidentiality agreements in connection with their employment, consulting or advisory relationships with us. We also require our
employees, consultants and advisors who we expect to work on our products to agree to disclose and assign to us all inventions
conceived during the work day, using our property or which relate to our business. We cannot provide any assurance that employees
and consultants will abide by the confidentiality or assignment terms of these agreements. Despite any measures taken to protect
our intellectual property, unauthorized parties may attempt to copy aspects of our products or to obtain and use information that
we regard as proprietary.
Patents
As
of December 31, 2012, we had fifty issued United States patents, nine pending patent applications or provisional patent applications
in the United States, eight issued European patents, seven issued Japanese patents and eleven foreign patent application families
as counterparts of U.S. cases. The issued and pending patents cover, among other things:
|
·
|
our method for performing trans-sacral procedures in the spine, including diagnostic or therapeutic
procedures, and trans-sacral introduction of instrumentation or implants;
|
|
·
|
apparatus for conducting these procedures including access, disc preparation and implantation including
the current TranS1 instruments individually and in kit form; and
|
|
·
|
implants for fusion and motion preservation in the spine; and
|
|
·
|
a direct lateral access and interbody fusion system.
|
Our
issued patents begin to expire in 2021 assuming timely payment of all maintenance fees. We have multiple patents covering unique
aspects and improvements for many of our methods and products. We do not believe that the expiration of any single patent is likely
to significantly affect our business, operating results or prospects.
Trademarks
We own nine trademark
registrations in the United States, nine trademark registrations in the European Union and two registered trademarks in Canada.
We also own two pending trademark application in the United States and four pending trademark applications in China.
Intellectual Property Licenses
We
license certain intellectual property that is used in some of our products, including our VEO Lateral Access and Interbody Fusion
System. We pay royalties on sales of licensed intellectual property that has been commercialized. We will continue to look to license
products or innovations that enhance our product offerings.
Government Regulation
Our
products are medical devices subject to extensive regulation by the FDA and other U.S. federal and state regulatory bodies
and comparable authorities in other countries. To ensure that medical products distributed domestically and internationally are
safe and effective for their intended use, the FDA and comparable authorities in other countries have imposed regulations that
govern, among other things, the following activities that we or our contract manufacturing partners perform and will continue to
perform:
|
·
|
product design and development;
|
|
·
|
establishment registration and device listing;
|
|
·
|
product testing (preclinical and clinical);
|
|
·
|
premarket clearance or approval;
|
|
·
|
advertising and promotion;
|
|
·
|
product marketing, sales and distribution; and
|
|
·
|
post-market surveillance, including reporting deaths or serious injuries related to products and certain product malfunctions.
|
FDA’s Premarket Clearance
and Approval Requirements
Unless
an exemption applies, each medical device we wish to commercially distribute in the United States will require either prior 510(k)
clearance or prior premarket approval from the FDA. The FDA classifies medical devices into one of three classes. Devices deemed
to pose lower risk are placed in either class I or II, which in many cases requires the manufacturer to submit to the FDA
a premarket notification requesting permission for commercial distribution. This process is known as requesting 510(k) clearance.
Some low risk devices are exempt from this requirement. Devices deemed by the FDA to pose the greatest risk, such as many life-sustaining,
life-supporting or implantable devices, or devices deemed not substantially equivalent to a legally marketable device, are placed
in class III, requiring a PMA. Our current commercial products are class II devices marketed under FDA 510(k) premarket
clearance or are Class I and exempt from 510(k) or PMA regulation. Premarket clearance applications are subject to the payment
of user fees, paid at the time of submission for FDA review.
510(k) Clearance
Pathway
To
obtain 510(k) clearance, we must submit a premarket notification demonstrating that the proposed device is substantially equivalent
to a legally marketable device not requiring a PMA. Although statutorily mandated to respond to a 510(k) premarket notification
within 90 days of submission of the application, the FDA’s 510(k) clearance pathway usually takes from three to twelve
months, or even longer, depending on the extent of requests for additional information by the FDA. Additional information can include
clinical data to make a determination regarding substantial equivalence.
After
a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would
constitute a new or change in its intended use, will require a new 510(k) clearance or, depending on the modification, require
a PMA. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k), or a PMA, but
the FDA can review any such decision and can disagree with a manufacturer’s determination. If the FDA disagrees with a manufacturer’s
determination, the FDA can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance
or a PMA is obtained. If the FDA requires us to seek 510(k) clearance or a PMA for any modifications to a previously cleared product,
we may be required to cease marketing or recall the modified device until we obtain this clearance or approval. Also, in these
circumstances, we may be subject to significant regulatory fines or penalties. We have made and plan to continue to make additional
enhancements to our products. We use the FDA’s guidance document on changes to approved devices to determine whether a change
requires a new submission.
Clinical
Trials
Clinical
trials are sometimes required for a 510(k) premarket notification. In the U.S., these trials require submission of an application
for an investigational device exemption, or IDE, unless the product is deemed a non-significant risk device eligible for more abbreviated
IDE requirements. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing
that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE application must be
approved in advance by the FDA for a specified number of patients. Clinical trials for a significant risk device may begin once
the IDE application is approved by the FDA and the appropriate institutional review boards at the clinical trial sites. Clinical
trials must be conducted in accordance with FDA regulations and federal and state regulations concerning human subject protection,
including informed consent and healthcare privacy and financial disclosure by clinical investigators. A clinical trial may be suspended
by FDA or the investigational review board at any time for various reasons, including a belief that the risks to the study participants
outweigh the benefits of participation in the study. Even if a study is completed, the results of our clinical testing may not
demonstrate the safety and efficacy of the device, or may be equivocal or otherwise not be sufficient to obtain clearance or approval.
Similarly, in Europe the clinical study must be approved by the local ethics committee and in some cases, including studies of
high-risk devices, by the Competent Authority in the applicable country.
Extensive
and Continuing FDA Regulation
After
a device is placed on the market, numerous FDA and other regulatory requirements continue to apply. These include:
|
·
|
quality system regulation, which requires manufacturers, including third-party contract manufacturers,
to follow stringent design, testing, control, documentation, and other quality assurance controls, during all aspects of the manufacturing
process;
|
|
·
|
establishment registration and listing;
|
|
·
|
labeling regulations, and FDA prohibitions against the promotion of products for uncleared or unapproved
“off-label” uses;
|
|
·
|
medical device reporting obligations, which require that manufacturers submit reports to the FDA
if information reasonably suggests that their device (i) may have caused or contributed to a death or serious injury, or (ii) malfunctioned
and the device or a similar company device would likely cause or contribute to a death or serious injury if the malfunction were
to recur; and
|
|
·
|
other post-market surveillance requirements, which apply when necessary to protect the public health
or to provide additional safety and effectiveness data for the device.
|
We
must register with the FDA as a medical device manufacturer and must obtain all necessary state permits or licenses to operate
our business. As manufacturers, we are subject to announced and unannounced inspections by the FDA to determine our compliance
with quality system regulation and other regulations. We were inspected by the FDA in May 2010 with no Form 483 observations. We
believe that we are in substantial compliance with quality system regulation and other regulations.
The
manufacturing facilities of our suppliers and contract manufacturer partners are also subject to announced and unannounced inspections
by the FDA. Our quality agreements with these partners obligate them to be in substantial compliance with U.S. regulations in this
area and none of our critical suppliers is undergoing any FDA enforcement action.
Fraud and
Abuse
We
may directly or indirectly be subject to various federal and state laws pertaining to healthcare fraud and abuse, including anti-kickback
laws. In particular, the federal healthcare program anti-kickback statute prohibits persons from knowingly and willfully soliciting,
offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual,
or the furnishing, arranging for or recommending a good or service, for which payment may be made in whole or part under federal
healthcare programs, such as the Medicare and Medicaid programs. The anti-kickback statute is broad and prohibits many arrangements
and practices that are lawful in businesses outside of the healthcare industry. In implementing the statute, the Office of Inspector
General, or OIG, has issued a series of regulations, known as the “safe harbors,” which began in July 1991. These safe
harbors set forth provisions that, if all their applicable requirements are met, will assure healthcare providers and other parties
that they will not be prosecuted under the anti-kickback statute. The failure of a transaction or arrangement to fit precisely
within one or more safe harbors does not necessarily mean that it is illegal or that prosecution will be pursued. However, conduct
and business arrangements that do not fully satisfy all requirements of an applicable safe harbor may result in increased scrutiny
by government enforcement authorities such as the OIG. Penalties for violations of the federal anti-kickback statute include criminal
penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal healthcare
programs.
The
federal False Claims Act prohibits persons from knowingly filing or causing to be filed a false claim to, or the knowing use of
false statements to obtain payment from, the federal government. Suits filed under the False Claims Act, known as “qui tam”
actions, can be brought by any individual on behalf of the government. These individuals, sometimes known as “relators”
or, more commonly, as “whistleblowers,” may share in any amounts paid by the entity to the government in fines or settlement.
The number of filings of qui tam actions has increased significantly in recent years, causing more healthcare companies to have
to defend a False Claim action. If an entity is determined to have violated the federal False Claims Act, it may be required to
pay up to three times the actual damages sustained by the government, plus civil penalties of between $5,500 and $11,000 for each
separate false claim. Various states have also enacted similar laws modeled after the federal False Claims Act which apply to items
and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.
The
Health Insurance Portability and Accountability Act of 1996, or
HIPAA, created two new federal crimes: healthcare fraud
and false statements relating to healthcare matters. The healthcare fraud statute prohibits knowingly and willfully executing a
scheme to defraud any healthcare benefit program, including private payors. A violation of this statute is a felony and may result
in fines, imprisonment or exclusion from government sponsored programs. The false statements statute prohibits knowingly and willfully
falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection
with the delivery of or payment for healthcare benefits, items, or services. A violation of this statute is a felony and may result
in fines or imprisonment.
We
are also subject to certain state laws that are analogous to each of the federal laws summarized above, such as anti-kickback and
false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers, and state
laws governing the privacy of certain health information, many of which differ from each other in significant ways and often are
not preempted by HIPAA, thus complicating compliance efforts.
While
we have adopted a comprehensive compliance program to attempt to comply with these laws and regulations, if any of our operations
are found to have violated or be in violation of any of the laws described above and other applicable state and federal fraud and
abuse laws, we may be subject to penalties, among them being civil and criminal penalties, damages, fines, exclusion from government
healthcare programs, and the curtailment or restructuring of our operations.
In October 2011, we
received a subpoena issued by the OIG, under the authority of the federal healthcare fraud and false claims laws. The subpoena
sought documents for the period January 1, 2008 through October 6, 2011. We have cooperated with the government’s request.
On December 24, 2012 we reached a tentative agreement in principle with the U.S. Department of
Justice related to the subpoena issued in October 2011. We tentatively agreed with the staff of the Department of Justice to settle
its federal investigation for $6 million, subject to completion and approval of written settlement agreements with the Department
of Justice and the OIG, which are expected to be finalized in the first half of 2013. We admit no wrongdoing as part of the settlement.
We are also unable to predict what impact, if any, the outcome of the matters raised by the OIG will have on the willingness
of surgeons to accept our products, our ability to hire or retain sales representatives and other employees, potential future reimbursement
decisions by payors or other significant aspects of our business.
International
International
sales of medical devices are subject to foreign government regulations, which vary substantially from country to country. The time
required to obtain approval by a foreign country may be longer or shorter than that required for FDA clearance or approval, and
the requirements may differ.
The
European Union, which consists of 27 of the major countries in Europe, has adopted numerous directives and standards regulating
the design, manufacture, clinical trials, labeling, and adverse event reporting for medical devices. Other countries, such as Switzerland,
have voluntarily adopted laws and regulations that mirror those of the European Union with respect to medical devices. Devices
that comply with the requirements of a relevant directive will be entitled to bear CE conformity marking and, accordingly, can
be commercially distributed throughout the member states of the European Union, and other countries that comply with or mirror
these directives. The method of assessing conformity varies depending on the type and class of the product, but normally involves
a combination of self-assessment by the manufacturer and a third-party assessment by a “Notified Body,” an independent
and neutral institution appointed to conduct conformity assessments. This third-party assessment consists of audits of the manufacturer’s
quality system for conformance to applicable quality system standards such as the Quality System, or ISO 13485, and compliance
of each product with the Medical Device Directive (MDD93/42/EEC as amended by directive 2007/47EC). In August 2004, our quality
system was initially certified by Intertek ETL-Semko, a Notified Body, under the European Union Medical Device Directive to be
in compliance with the Canadian Medical Device Conformity Assessment System, or CMDCAS, and ISO 13485. A surveillance audit in
September of 2012 found no major non-conformities and the system is due for further recertification in September of 2013.
Registration
of our products has been completed, or is currently in process, for other countries such as Brazil, China, India, Israel, Japan,
Mexico and Russia.
Employees
As
of December 31, 2012, we had 89 employees, 88 of whom were full-time employees, with 47 employees in U.S. sales, marketing,
professional affairs, customer service and training, 2 employees in international sales and management, 3 employees in operations,
11 employees in research and development, 14 employees in general and administrative and 12 employees in clinical, regulatory
and quality assurance. We believe that our future success will depend in part on our continued ability to attract, hire and retain
qualified personnel. None of our employees are represented by a labor union, and we believe that we maintain good relations with
our employees. Effective January 1, 2012, we replaced our direct sales representatives in Europe with an independent sales agent,
comprised of former employees of our direct sales organization, representing Germany, Netherlands, and Belgium. In January 2013,
we terminated this sales agent and are transitioning to other distribution channels in these regions.
General Information
We
were incorporated in Delaware in May 2000 under the name “aXiaMed, Inc.” and changed our name to “TranS1 Inc.”
in February 2003. Effective March 1, 2013, our principal executive office is located at 110 Horizon Drive, Suite 230, Raleigh,
North Carolina 27615 and our telephone number is (866) 256-1206. Our website is
www.trans1.com
. The information on, or that
can be accessed through, our website is not incorporated by reference into this annual report and should not be considered to be
a part of this annual report.
We
make our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to these reports
available on our website, at
www.trans1.com
, free of charge as soon as practicable after filing with the SEC.
All
such reports are also available free of charge via EDGAR through the SEC website at www.sec.gov. In addition, the public may read
and copy materials filed by us with the SEC at the SEC’s public reference room located at 100 F St., NE, Washington, D.C.,
20549. Information regarding operation of the SEC’s public reference room can be obtained by calling the SEC at 1-800-SEC-0330.
Investing
in our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other
information contained in this annual report, before deciding whether to invest in shares of our common stock. If any of the following
risks actually occur, our business, financial condition, operating results and prospects would suffer. In that case, the trading
price of our common stock would likely decline and you might lose all or part of your investment in our common stock. The risks
described below are not the only ones we face. Additional risks that we currently do not know about or that we currently believe
to be immaterial may also impair our operations and business results.
Risks Related to Our Business
To be commercially successful, spine
surgeons must accept that our products are a safe and effective alternative to other surgical treatments of certain spine disorders.
Our revenue is primarily derived from sales
of our AxiaLIF and VEO products and related surgical instruments. We expect that sales of our AxiaLIF and VEO products will continue
to account for a substantial portion of our revenues for the foreseeable future. We believe spine surgeons may not widely adopt
our products unless they determine, based on experience, long-term clinical data and published peer reviewed journal articles,
that our products provide a safe and effective alternative to conventional procedures used to treat certain spine disorders or
other non-conventional procedures offered by our competitors. Spine surgeons may be slow to adopt our technology for the following
reasons, among others:
|
·
|
lack of long-term clinical data supporting additional patient benefits;
|
|
·
|
lack of experience with our products;
|
|
·
|
lack of evidence supporting the cost savings, clinical efficacy or safety of our products and procedure
over competitive products and medical technologies;
|
|
·
|
perceived liability risks generally associated with the use of new products and procedures;
|
|
·
|
training time required to use a new product or procedure; and
|
|
·
|
availability of adequate coverage and reimbursement for hospitals and surgeons.
|
If we are unable to effectively demonstrate
to spine surgeons the benefits of our products as compared to other surgical treatments
of
spine disorders that are available to them and our products fail to achieve market acceptance, our future revenues will be adversely
impacted. In addition, we believe recommendations and support of our products by influential spine surgeons are essential for market
acceptance and adoption. If we do not receive support from these spine surgeons or do not have favorable long-term clinical data,
spine surgeons may not use our products and our future revenues will be harmed, which could result in a decline in the price of
our common stock.
The efficacy of our products is not
yet supported by long-term clinical data and may therefore prove to be less effective than initially thought.
We obtained 510(k) clearance to manufacture,
market and sell all of our currently U.S. marketed products for which FDA clearance is required. In order to obtain 510(k) clearance,
a manufacturer must demonstrate to the FDA’s satisfaction that its device is “substantially equivalent” to other
legally marketed devices not requiring a PMA. In contrast, certain high-risk and/or new devices require submission of a PMA application
to the FDA. Such a PMA application must demonstrate that the device is safe and effective for the proposed indication, and must
be supported by extensive data from preclinical studies and human clinical trials. The FDA’s 510(k) clearance process is
therefore less costly and rigorous than the PMA process and requires less supporting clinical data. Because our devices were cleared
for marketing through the 510(k) process or were exempt from the 510(k) process, we currently lack the breadth of published long-term
clinical data supporting the efficacy of our AxiaLIF and VEO products and the benefits they offer that might have been generated
in connection with the PMA process.
The demand for our products and the
prices that customers and patients are willing to pay for our products depend upon the ability of our customers to obtain adequate
third-party coverage and reimbursement for their purchases of our products.
Sales of our products depend in part on
the availability of adequate coverage and reimbursement from governmental and private payors. In the United States, healthcare
providers that purchase our products generally rely on third-party payors, principally Medicare, Medicaid and private health insurance
plans, to pay for all or a portion of the costs and fees associated with our AxiaLIF and VEO procedures.
Physicians generally use billing codes
known as CPT codes to report professional services rendered for reimbursement purposes. The CPT coding system is maintained and
updated on an annual basis by the Panel. In 2008, most of the surgeons performing our AxiaLIF procedure billed third-party payors
using existing ALIF procedure codes. Effective January 1, 2009, the AMA, however, created a new emerging technology CPT code —
or Category III code — to facilitate data collection on and assessment of new services and procedures such as the AxiaLIF
procedure. This change made it more difficult for physicians to obtain reimbursement for our AxiaLIF procedure because many commercial
payors view a Category III code as “experimental” or “investigational” and thus will not pre-approve the
procedure or will decline to pay for the procedure until they see additional clinical evidence. This uncertainty around the availability
and amount of reimbursement has caused some physicians to revert to other fusion surgeries where coverage and reimbursement are
more certain. We made a presentation to the Panel at their October 2011 meeting, asking them to consider transitioning the Category
III code to a permanent Category I code for our AxiaLIF procedures. On November 8, 2011, we received notice from the AMA that the
Panel rejected our request to convert Category III codes 0195T and 0196T, used to bill for the service in which our product is
used, to Category I codes. We subsequently presented to the Panel at their February 2012 meeting, again asking them to consider
transitioning the Category III code to a permanent Category I code for our AxiaLIF procedures. On March 5, 2012, we announced that
the Panel voted to approve an application for a new Category I CPT code, 22586, for L5/S1 spinal fusion utilizing our AxiaLIF implant
when performing a pre-sacral interbody fusion. In addition, the Panel voted to establish a new Category III CPT code, 0309T, as
an add-on code to the new Category I code for use with 22586 when performing L4/5 spinal fusion. The new CPT codes were announced
on the AMA’s website on March 2, 2012 and became effective on January 1, 2013. The Medicare final rule was released in November
2012, which stated a
valuation of the Category I CPT code 22586 for pre-sacral
interbody single level spinal fusion at L5-S1, and
became effective January 1, 2013. This
CPT
code, which applies to our AxiaLIF Plus 1-Level device, is a bundled lumbar arthrodesis procedure that includes bone graft, posterior
instrumentation and fixation.
Third-party payors continue to review their
coverage policies carefully for existing and new therapies and can, without notice, deny coverage for treatments that include the
use of our products. While we have received several positive coverage and reimbursement decisions from payors for the use of our
products during the period from January 2012 through February 2013 and are currently engaged in discussions with other payors,
it is difficult to predict the timing of receiving any additional positive coverage decisions and there is no guarantee that payors
will make any additional positive coverage decisions. Our business would be negatively impacted to the extent any such coverage
decisions reduce our customers’ ability to obtain coverage and reimbursement for the procedures using our products. In addition,
our stock price could be negatively affected to the extent that coverage decisions by payors do not reflect market expectations
for such decisions.
With respect to coverage and reimbursement
outside of the United States, reimbursement systems in international markets vary significantly by country, and by region within
some countries, and reimbursement approvals must be obtained on a country-by-country basis and can take up to 18 months, or longer.
Many international markets have government-managed healthcare systems that govern reimbursement for new devices and procedures.
In most markets, there are private insurance systems as well as government-managed systems. Additionally, some foreign reimbursement
systems provide for limited payments in a given period and therefore result in extended payment periods. Reimbursement in international
markets may require us to undertake country-specific reimbursement activities, including additional clinical studies, which could
be time consuming, expensive and may not yield acceptable reimbursement rates.
Furthermore, healthcare costs have risen
significantly over the past decade. There have been and may continue to be proposals by legislators, regulators and third-party
payors to contain these costs. These cost-control methods include prospective payment systems, capitated rates, group purchasing,
redesign of benefits, pre-authorizations or second opinions prior to major surgery, encouragement of healthier lifestyles and exploration
of more cost-effective methods of delivering healthcare. Some healthcare providers in the United States have adopted or are considering
a managed care system in which the providers contract to provide comprehensive healthcare for a fixed cost per person. Healthcare
providers may also attempt to control costs by authorizing fewer elective surgical procedures or by requiring the use of the least
expensive devices possible. These cost-control methods also potentially limit the amount that healthcare providers may be willing
to pay for certain types of medical procedures.
In addition, in the United States, no uniform
policy of coverage and reimbursement for medical technology exists among payors. Therefore, coverage of and reimbursement for medical
technology can differ significantly for each payor. The continuing efforts of third-party payors, whether governmental or commercial,
whether inside the United States or outside, to contain or reduce these costs, combined with closer scrutiny of such costs, could
restrict our customers’ ability to obtain adequate coverage and reimbursement from these third-party payors. The cost containment
measures that healthcare providers are instituting both in the United States and internationally could harm our business by adversely
affecting the demand for our products or the price at which we can sell our products.
Reforms to the United States healthcare system may adversely
affect our business.
The healthcare industry continues to undergo
significant changes designed to increase access to medical care, improve safety, and contain costs. In March 2010, U.S. President
Barack Obama signed the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation
Act, or collectively, the Health Care Reform Law, which makes a number of substantial changes in the way healthcare is financed
by both governmental and private insurers. Among other things, the Health Care Reform Law requires medical device manufacturers
to pay a sales tax equal to 2.3% of the price for which such manufacturer sells its medical devices, beginning January 1, 2013.
Other provisions of this legislation, including Medicare provisions aimed at improving quality and decreasing costs, comparative
effectiveness research, an independent payment advisory board, and pilot programs to evaluate alternative payment methodologies,
could meaningfully change the way healthcare is developed and delivered, and may adversely affect our business and results of operations.
Certain provisions of the legislation will not be effective for a number of years, the details of many programs and requirements
have not yet been fully established, and we cannot predict the full impact of the legislation. We anticipate that many of the provisions
in the Health Care Reform Law will be subject to further clarification and modification through the rule-making process, the development
of agency guidance, and judicial interpretations.
In addition, other legislative and regulatory
changes have resulted in limitations on and, in some cases, reductions in levels of payments to healthcare providers for certain
services under the Medicare program. On August 2, 2011, the President signed into law the Budget Control Act of 2011, which, among
other things, created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress.
The Joint Select Committee was unable to achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through
2021, thereby triggering an automatic reduction in spending programs. These automatic cuts will be made to several government programs
and, with respect to Medicare, would include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year.
These automatic cuts were scheduled to start on January 2, 2013, but the American Taxpayer Relief Act of 2012 delayed the start
date to March 1, 2013. We are unable to predict how these spending reductions will be structured, what other deficit reduction
initiatives may be proposed by Congress, or whether Congress will attempt to further suspend or restructure the automatic budget
cuts. Additionally, the current economic environment has increased the budgetary pressures on many states, and these budgetary
pressures have resulted, and likely will continue to result, in decreased spending, or decreased spending growth, for Medicaid
programs in many states.
Further federal and state proposals for
healthcare reform are likely. We cannot predict what further reform proposals, if any, will be adopted, when they may be adopted,
or what impact they may have on us. However, any changes that lower reimbursements for our products or reduce medical procedure
volumes could adversely affect our business and results of operations.
We have incurred losses since inception
and we expect to continue to incur losses for the foreseeable future. We may never achieve or sustain profitability.
We have incurred net losses since our
inception in May 2000 and we have an accumulated deficit of $138.8 million through December 31, 2012. As a result of our operating
losses and negative cash flows, the report of our independent registered public accounting firm on the financial statements as
of and for the year ended December 31, 2012, included an explanatory paragraph indicating that there is substantial doubt about
our ability to continue as a going concern. To date, we have financed our operations primarily through sales of our equity securities,
including the sale of 6,200,000 shares of our common stock for aggregate net proceeds of approximately $18.2 million in September
2011, and have devoted substantially all of our resources to research and development of our products, the commercial launch of
our products and the development of a sales team to market our products. We expect our expenses to increase in connection with
our clinical trials and research and development activities, as well as to support our sales and marketing efforts. As a result,
we expect to continue to incur operating losses for the foreseeable future. These losses will continue to have an adverse effect
on our stockholders’ equity and we may never achieve or sustain profitability.
We are in a highly competitive market
segment, which is subject to rapid technological change.
The market for treatment of spine disorders
is highly competitive and subject to rapid and profound technological change. Our success depends, in part, upon our ability to
maintain a competitive position in the development of technologies and products for use in the treatment of spine disorders. We
face competition from both established and development stage companies. Many of these companies have competitive advantages, including:
|
·
|
greater financial and human resources for product development, sales and marketing and patent litigation;
|
|
·
|
significantly greater name recognition;
|
|
·
|
established relationships with spine surgeons, customers and third-party payors;
|
|
·
|
reimbursement codes providing for adequate coverage and reimbursement to hospitals and surgeons;
|
|
·
|
additional lines of products, and the ability to offer rebates or bundle products to offer greater
discounts or incentives to gain a competitive advantage;
|
|
·
|
established sales and marketing, and distribution networks; and
|
|
·
|
greater experience in developing new products, conducting clinical trials, preparing regulatory
submissions and obtaining regulatory clearance or approval for products and marketing approved products.
|
Our ability to compete successfully will
depend on our ability to develop proprietary products that reach the market in a timely manner, receive adequate reimbursement,
and demonstrate that our products are safer and less invasive than alternatives available for the same purpose. Because of the
size of the potential market, we anticipate that companies will dedicate significant resources to developing competing products.
If we cannot successfully introduce new products, adapt to changing technologies, or anticipate changes in our current and potential
customers’ requirements, our products may become obsolete and our business could suffer.
Our failure to continue building effective
sales and marketing capabilities for our products could significantly impair our ability to increase sales of our products.
We utilize
a hybrid model of independent sales agents and direct sales representatives for product sales in the United States and rely on
third-party distributors and independent sales agents for international sales. As of December 31, 2012, we employed 26 direct sales
representatives,
one case coverage specialist, three regional managers
and two area
vice-presidents
in the United States. Effective January 1, 2012, we converted our direct sales
representatives in Europe to an independent sales agent, representing Germany, Netherlands, and Belgium. In January 2013, we terminated
this sales agent and are transitioning to other distribution channels in those regions. If we are unable to efficiently manage
our sales representatives, our sales will suffer.
We also rely on marketing arrangements
with independent sales agents in the United States and independent distributors in Europe. We do not control, nor monitor the marketing
practices of our independent sales agents or distributors and they may not be successful in implementing our marketing plans or
complying with applicable laws regarding marketing practices. Independent distributors and sales agents may terminate their relationship
with us, or devote insufficient sales efforts to our products, which could have an adverse effect on our operations.
Our future success depends on our ability
to develop, receive regulatory clearance or approval for, and introduce new products or product enhancements that will be accepted
by the market in a timely manner.
It is important to our business that we
continue to build a more complete product offering for treatment of spine disorders. As such, our success will depend in part on
our ability to develop and introduce new products and enhancements to our existing products to keep pace with the rapidly changing
spine market. However, we may not be able to successfully develop and obtain regulatory clearance or approval for product enhancements,
or new products, or these products may not be accepted by spine surgeons or payors who financially support many of the procedures
performed with our products.
The success of any new product offering
or enhancement to an existing product will depend on several factors, including our ability to:
|
·
|
properly identify and anticipate spine surgeon and patient needs;
|
|
·
|
develop and introduce new products or product enhancements in a timely manner;
|
|
·
|
avoid infringing upon the intellectual property rights of third parties;
|
|
·
|
demonstrate the safety and efficacy of new products with data from preclinical studies and clinical
trials;
|
|
·
|
obtain the necessary regulatory clearances or approvals for new products or product enhancements;
|
|
·
|
be fully FDA-compliant with marketing of new devices or modified products;
|
|
·
|
provide
adequate training
to potential users
of our products;
|
|
·
|
receive
adequate coverage
and reimbursement
for procedures
performed with
our products; and
|
|
·
|
develop
an effective and
FDA-compliant,
dedicated marketing
and distribution
network.
|
If we do not develop new products or product
enhancements in time to meet market demand or if there is insufficient demand for these products or enhancements, our results
of operations will suffer.
If clinical trials of our current or
future product candidates do not produce results necessary to support regulatory clearance or approval in the United States or
elsewhere, we will be unable to commercialize these products.
Clinical failure can occur at any stage
of the testing. Our clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require
us, to conduct additional clinical and/or non-clinical testing in addition to those we have planned. Our failure to adequately
demonstrate the efficacy and safety of any of our devices would prevent or significantly delay receipt of regulatory clearance
or approval and, ultimately, the commercialization of that device.
Our international operations subject
us to certain operating risks, which could adversely impact our net revenues, results of operations and financial condition.
Sales of our products outside the United
States represented 13.2% of our revenue in 2012. The sale and shipment of our products across international borders, as well as
the purchase of components and products from international sources, subject us to extensive U.S. and foreign governmental trade,
import and export, and customs regulations and laws. Compliance with these regulations is costly and exposes us to penalties for
non-compliance. Other laws and regulations that can significantly impact us include various anti-bribery laws, including the U.S.
Foreign Corrupt Practices Act and anti-boycott laws. Any failure to comply with applicable legal and regulatory obligations could
impact us in a variety of ways that include, but are not limited to, civil and administrative penalties, denial of export privileges,
seizure of shipments and restrictions on certain business activities.
Our international operations expose us
and our distributors to risks inherent in operating in foreign jurisdictions. These risks include:
|
·
|
the
imposition of additional
U.S. and foreign
governmental controls
or regulations;
|
|
·
|
the
imposition of complicated
and
costly export
licensing requirements;
|
|
·
|
the
imposition of U.S.
or international
sanctions against
a country, company,
person or entity
with whom we do
business that would
restrict or prohibit
continued business
with the sanctioned
country, company,
person or entity;
|
|
·
|
economic
weakness or uncertainty,
including the sovereign
debt crises affecting
several countries
in the European
Union;
|
|
·
|
changes
in third-party
reimbursement policies
that may require
some of the patients
who receive our
products to directly
absorb medical
costs or that may
necessitate the
reduction of the
selling prices
of our products;
|
|
·
|
changes
in duties and tariffs,
license obligations
and other non-tariff
barriers to trade;
|
|
·
|
the
imposition of new
trade restrictions;
|
|
·
|
the
imposition of restrictions
on the activities
of foreign agents,
representatives
and distributors;
|
|
·
|
difficulties
in maintaining
consistency with
our internal guidelines;
|
|
·
|
complications
arising from enforcing
agreements and
collecting receivables
through certain
foreign legal systems;
and
|
|
·
|
uncertainties
surrounding the
enforcement or
defense of our
intellectual property
rights.
|
There can be no assurance that the foregoing
factors will not adversely affect our operations in the future or require us to modify our anticipated business practices.
We purchase some of the key components
of our products from single suppliers. The loss of these suppliers could prevent or delay shipments of our products or delay our
clinical trials or otherwise adversely affect our business.
Due to quality considerations, costs,
or constraints resulting from regulatory requirements, some of the key components of our products are currently purchased from
only single suppliers with which we do not have long-term contracts. Some of these suppliers may be located outside of the United
States, which could make us subject to foreign export laws and U.S. import and customs statutes and regulations, thus complicating
and delaying shipments of components. Any of our supplier relationships could be interrupted due to events beyond our control,
including natural disasters, or could be terminated. In addition, we may lose a single supplier due to, among other things, the
acquisition of such a supplier by a competitor (which may cause the supplier to stop selling its products to us) or the bankruptcy
of such a supplier, which may cause the supplier to cease operations. If necessary or desirable, we could source our product components
and related services from other suppliers. However, establishing additional or replacement suppliers for these components, and
obtaining any necessary regulatory clearances or approvals, could take a substantial amount of time and could result in increased
costs and impair our ability to produce our products, which would adversely impact our business, operating results and prospects.
If our independent contract manufacturers
fail to deliver to us sufficient quantities of some of our products and components in a timely manner, our operations may be harmed.
Our reliance on independent contract manufacturers
to manufacture most of our products and components involves several risks, including:
|
·
|
inadequate
capacity of the
manufacturer’s
facilities;
|
|
·
|
financial
difficulties experienced
by manufacturers
due to the current
economic weakness
and uncertainty;
|
|
·
|
interruptions
in access to certain
process technologies;
and
|
|
·
|
reduced
control over product
availability, quality,
delivery schedules,
manufacturing yields
and costs.
|
Shortages
of raw materials, production capacity or financial constraints, or delays by our contract manufacturers could negatively affect
our ability to meet our production obligations and result in increased prices for affected parts. Any such reduction, constraint
or delay may result in delays in shipments of our products or increases in the prices of components, either of which could have
a material adverse effect on our business.
In addition, we could be forced to secure new or alternative contract manufacturers
or suppliers. Securing a replacement contract manufacturer or supplier could be difficult. The introduction of new or alternative
manufacturers or suppliers also may require design changes to our devices that are subject to FDA and other regulatory clearances
or approvals. We may also be required to assess the new manufacturer’s compliance with all applicable regulations and guidelines,
which could further impede our ability to manufacture our products in a timely manner. As a result, we could incur increased production
costs, experience delays in deliveries of our products, suffer damage to our reputation and experience an adverse effect on our
business and financial results.
We depend on the specialized knowledge
and skills of our officers and other key employees, and if we are unable to retain and motivate them or recruit additional qualified
personnel, our business will suffer.
We are highly dependent on our officers
and other key employees. Due to the specialized knowledge and skills each of our officers and other key employees possesses with
respect to the treatment of spine disorders and our operations, the loss of service of any of our officers and other key employees
could delay or prevent the successful completion of our clinical trials, the growth of revenue from existing products and the
commercialization of our new products. This risk may be exacerbated by the fact that our principal offices are located in a smaller
metropolitan area, which could make it more difficult for us to retain employees or attract new employees with the required set
of skills. Each of our officers and key employees may terminate his or her employment without notice and without cause or good
reason.
We will need to raise additional capital
in the future and, if we are unable to raise capital, it could force us to delay, reduce, eliminate or abandon our commercialization
efforts or product development programs.
We believe that our existing cash and
cash equivalent balances and cash receipts generated from sales of our products will be insufficient to meet our anticipated cash
requirements through 2013. If the Merger and Private Placement Transaction are consummated as currently planned, however, we believe
that we will be able to meet our anticipated cash requirements through mid-2014. Our future funding requirements will depend on
many factors, including:
|
·
|
market
acceptance of our
products and the
revenues we are
able to generate
as a result;
|
|
·
|
the
availability of
adequate coverage
and reimbursement
for hospitals and
surgeons;
|
|
·
|
the
scope, rate of
progress and cost
of our clinical
trials;
|
|
·
|
the
cost of our research
and development
activities;
|
|
·
|
the
cost of defending,
in litigation or
otherwise, any
claims that we
infringe third-party
patent or other
intellectual property
rights;
|
|
·
|
the
cost and timing
of additional regulatory
clearances or approvals;
and
|
|
·
|
the
cost and timing
of establishing
additional sales,
marketing and distribution
capabilities.
|
As a result of the recent economic recession,
and the continuing economic uncertainty, it has been difficult for many companies to obtain equity or debt financing. If we raise
additional funds by issuing equity or convertible debt securities, our stockholders may experience dilution and the securities
may contain terms that are preferential to the new investors as compared to the holders of our common stock. If we raise additional
funds by issuing debt securities, the securities may have rights senior to those associated with our common stock and contain
covenants restricting our operations, our ability to pay dividends, the amount of capital expenditures we can make, or our ability
to incur additional debt. Any debt financing or additional equity that we raise may contain terms that are not favorable to us
or our stockholders. In addition, if we raise additional funds through collaboration and licensing arrangements with third parties,
it may be necessary to relinquish some rights to our technologies or our products, or grant licenses on terms that are not favorable
to us. If we are unable to raise adequate funds, we may have to delay, reduce the scope of or eliminate some or all of our planned
product development and marketing efforts. Additionally, if we do not have, or are not able to obtain, sufficient funds, we may
have to delay development or commercialization of our products or license to third parties the rights to commercialize products
or technologies that we would otherwise seek to commercialize. We also may have to reduce marketing, customer support or other
resources devoted to our products or cease operations.
Our independent registered public accounting firm has indicated
that our recurring losses from operations raise substantial doubt about our ability to continue as a going concern.
Our audited financial statements for the
fiscal year ended December 31, 2012, were prepared on the basis that our business would continue as a going concern in accordance
with accounting principles generally accepted in the United States, or GAAP. This basis of presentation assumes that we will continue
in operation for the foreseeable future and will be able to realize our assets and discharge our liabilities and commitments in
the normal course of business. However, our independent registered public accounting firm has indicated in their audit report
on our fiscal 2012 financial statements that our recurring losses from operations raise substantial doubt about our ability to
continue as a going concern. We may be forced to delay or limit planned product development, marketing or product commercialization
efforts, pursue a plan to license or sell our assets, cease our operations and/or seek bankruptcy protection if we are unable
to raise additional funding to meet our working capital needs. However, we cannot guarantee that we will be able to obtain sufficient
additional funding when needed or that such funding, if available, will be obtainable on terms satisfactory to us. In the event
that our funding plans cannot be effectively realized, there can be no assurance that we will be able to continue as a going concern.
Pricing pressures in the healthcare
industry could lead to further demands for price concessions and restricted access to spinal fusions, which could have an adverse
effect on our business, financial condition or results of operations.
Because healthcare costs have risen significantly
over the past decade, numerous initiatives and reforms initiated by legislators, regulators and third-party payors to curb these
costs have resulted in difficulty in raising or maintaining prices and procedure volumes. As total spine volume growth has begun
to subside, many larger companies have cut prices as they struggle to retain market share, which has led to increased pricing
pressure. Decreasing healthcare utilization as a result of the economic downturn, high unemployment rates, a reduction in the
ranks of the full-time employed and the expiration of COBRA benefits has limited the number of patients that are covered for procedures
and patients with coverage are faced with increasing deductibles. Additionally, potential patients are increasingly concerned
about an extended absence from work, which would be typical of major surgery like lumbar fusion. The spine market generally, and
lumbar fusion market in particular, has seen increasing push back from payors with regard to coverage. Spine surgery is a major
cost area for payors, and from 2001 to 2008, lumbar fusions for lower back pain grew more than twice as fast as other lumbar fusions.
As a result, private payors have increased the criteria that a patient must meet in order to be pre-authorized for lumbar fusion
procedures and have put more effort into the preauthorization process. Payors have specifically stopped covering lumbar spine
procedures involving degenerative disc disease patients that have no other symptoms such as leg pain or general spinal instability.
In addition, as a result of significant consolidation in the medical technology industry, group purchasing organizations and integrated
health delivery networks have served to concentrate purchasing decisions for some customers, which has also placed pricing pressure
on medical device suppliers. We expect that market demand, government regulation, third-party reimbursement policies, industry
consolidation and societal pressures will continue to exert downward pressure on the prices of our products and may adversely
impact our business, financial condition or results of operations.
We face the risk of product liability
or other claims and may not be able to obtain sufficient insurance coverage, if at all.
Our business exposes us to the risk of
product liability claims that is inherent in the testing, manufacturing and marketing of implantable medical devices. We may be
subject to product liability claims if our products cause, or merely appear to have caused, an injury or death. Claims may be
made by patients, consumers or healthcare providers. Although we have product liability and clinical trial liability insurance
that we believe is appropriate for our current level of operations, this insurance is subject to deductibles and coverage limitations.
Our current product liability insurance may not continue to be available to us on acceptable terms, if at all, and, if available,
these coverages may not be adequate to protect us against any future product liability claims.
Further, we may be subject to claims against
us even if the apparent injury is due to the actions of others. For example, we rely on the expertise of spine surgeons, nurses
and other associated medical personnel to perform the medical procedure and related processes for our products. If these medical
personnel are not properly trained or are negligent in their provision of care, the therapeutic effect of our products may be
diminished or the patient may suffer critical injury, which may subject us to liability. In addition, an injury that is caused
by the activities of our suppliers may be the basis for a claim against us.
These liabilities could prevent, delay
or otherwise adversely interfere with our product commercialization efforts, and result in judgments, fines, damages and other
financial liabilities which have adverse effects on our business, operating results and prospects.
We operate primarily at two locations.
Any disruption in these facilities could adversely affect our business and results of operations.
Our main offices are located in Raleigh,
North Carolina and Wilmington, North Carolina. Our Raleigh, N.C. location includes a corporate office and training facility. If
the Merger and Private Placement Transaction are consummated as currently planned, we will acquire a third facility in San Jose,
California. Our facilities may be affected by man-made or natural disasters, such as a hurricane. Our facilities, if damaged or
destroyed, could require substantial lead-time to repair or replace. Although we believe we possess adequate insurance for damage
to our property and the disruption of our business from casualties, this insurance may not be sufficient to cover all of our potential
losses and may not continue to be available to us on acceptable terms, or at all.
Our
business and our results of operations
could be materially adversely affected as a result of general economic and
market conditions, including the current economic environment.
Current economic conditions
could
adversely affect our business and our results of operations
. Among other things, the potential decline in federal and state
revenues that may result from such conditions may create additional pressures to contain or reduce reimbursements for our products
from Medicare, Medicaid, and other government sponsored programs. Increasing job losses or slow improvement in the unemployment
rate in the U.S. as a result of current or recent economic conditions has and may continue to result in a smaller percentage of
our patients being covered by an employer group health plan and a larger percentage being covered by lower paying Medicare and
Medicaid programs. Employers may also begin to select more restrictive commercial plans with lower reimbursement rates. To the
extent that payors are negatively impacted by a decline in the economy, we may experience further pressure on commercial rates,
a further slowdown in collections, and a reduction in the amounts we expect to collect. Any or all of these factors, as well as
other consequences of the current economic condition that cannot currently be anticipated, could have a material
adverse
effect on our revenues
, earnings, and cash flows and otherwise adversely affect our financial condition.
A security breach or other disruption
of our information technology systems could disrupt our business, compromise our information, and expose us to liability, which
would cause our business and reputation to suffer.
We rely on information technology systems
to process, transmit, and store electronic information in our day-to-day operations. Despite our security measures, our information
technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance, or other
disruptions. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed,
lost, or stolen. Any such access, disclosure, or other loss of information could result in legal claims or proceedings, disrupt
our operations, and damage our reputation, which could adversely affect our revenues and competitive position. While we have
policies and procedures designed to prevent or limit the effect of the failure, interruption, or security breach of our information
technology systems, there can be no assurance that we can prevent any such failures, interruptions, or security breaches or, if
they do occur, that they will be adequately addressed.
Risks Related to the Regulatory Environment
If we fail to maintain regulatory approvals
and clearances, or are unable to obtain, or experience significant delays in obtaining, FDA clearances or approvals for our future
products or product modifications, our ability to commercially distribute and market our products could suffer.
Our products are subject to rigorous regulation
by the FDA and numerous other federal, state and foreign governmental authorities. The process of obtaining regulatory clearances
or approvals to market a medical device can be costly and time consuming, and we may not be able to obtain these clearances or
approvals on a timely basis, if at all. In particular, the FDA permits commercial distribution of most new medical devices only
after the device has received clearance under Section 510(k) of the Federal Food, Drug and Cosmetic Act, or is the subject of
an approved PMA. The FDA will clear marketing of a non-exempt lower risk medical device through the 510(k) process if the manufacturer
demonstrates that the new product is substantially equivalent to other legally marketed products not requiring PMA approval. Our
currently commercialized products that are not exempt have been cleared through the 510(k) process. However, we may need to submit
a PMA for future products we develop. The PMA process is more costly, lengthy and uncertain than the 510(k) clearance process.
A PMA application must be supported by extensive data, including, but not limited to, technical, preclinical, clinical trial,
manufacturing and labeling data, to demonstrate to the FDA’s satisfaction the safety and efficacy of the device for its
intended use.
Some of our new products will require
FDA clearance through the 510(k) process. Other products may require the approval of a PMA. In addition some of our new products
may require clinical trials to support regulatory approval and we may not successfully complete these clinical trials. The FDA
may not approve or clear these products for the indications that are necessary or desirable for successful commercialization.
The FDA may refuse our requests for 510(k) clearance or premarket approval of new products. Failure to receive clearance or approval
for our new products would have an adverse effect on our ability to expand our business.
Any modification to our currently marketed
510(k)-cleared devices that could significantly affect their safety or efficacy, or that would constitute a change in their intended
use, requires a new 510(k) clearance or, possibly, a PMA. The FDA requires every manufacturer to make this determination in the
first instance, but the FDA may review the manufacturer’s decision. The FDA may not agree with our decisions regarding whether
new clearances or approvals are necessary. If the FDA requires us to seek 510(k) clearance or a PMA for any modification to a
previously cleared product, we may be required to cease marketing and distributing, or to recall the modified product until we
obtain such clearance or approval, and we may be subject to significant regulatory fines or penalties.
If
the FDA disagrees and requires new clearances or approvals for the modifications, we may be required to recall and stop marketing
our products as modified, which could require us to redesign our products and harm our operating results. In these circumstances,
we may be subject to significant enforcement actions.
Where we determine that modifications
to our products require a new 510(k) clearance or premarket approval application, we may not be able to obtain those additional
clearances or approvals for the modifications or additional indications in a timely manner, or at all. For those products sold
in the European Union, or E.U., we must notify our E.U. Notified Body if significant changes are made to the products or if there
are substantial changes to our quality assurance systems affecting those products. Obtaining clearances and approvals can be a
time consuming process, and delays in obtaining required future clearances or approvals would adversely affect our ability to
introduce new or enhanced products in a timely manner, which in turn would harm our future growth.
The failure by us or one of our suppliers
to comply with U.S. federal, state, and foreign governmental regulations could lead to the imposition of injunctions, suspensions
or loss of regulatory clearance or approvals, product recalls, termination of distribution, product seizures or civil penalties,
among other things. In the most extreme cases, criminal sanctions or closure of our manufacturing facility are possible. To the
extent one of our suppliers fails to comply with applicable U.S. federal, state and foreign regulations, it may affect our ability
either to obtain components and/or finished products or to have our finished products manufactured. In addition, changes in governmental
policies or regulations may impose additional regulatory requirements on us, which could delay our ability to obtain new clearances
or approvals and increase the costs of compliance. For instance, the FDA recently clarified the regulatory requirements to obtain
510(k) clearances and PMA approval. These two new guidance documents may make it more difficult for us to apply for and receive
510(k) clearances and PMA approvals for our new devices and to commercialize modifications to our existing devices. Additionally,
the Food and Drug Administration Amendments Act of 2007 requires, among other things, that the FDA propose, and ultimately implement,
regulations that will require manufacturers to label medical devices with unique identifiers unless a waiver is received from
the FDA. Once implemented, compliance with those regulations may require us to take additional steps in the manufacture of our
products and labeling. These steps may require additional resources and could be costly.
Further, foreign governmental authorities
that regulate the manufacture and sale of medical devices have become increasingly stringent and, to the extent we market and
sell our products internationally, we may be subject to rigorous international regulation in the future. In these circumstances,
we rely significantly on our foreign independent distributors to comply with the varying regulations, and any failures on their
part could result in restrictions on the sale of our products in foreign countries. Approval or clearance by the FDA does not
ensure approval by regulatory authorities in other jurisdictions, and approval by one foreign regulatory authority does not ensure
approval by regulatory authorities in other foreign jurisdictions or by the FDA. The foreign regulatory approval process may include
all of the risks associated with obtaining FDA approval in addition to other risks. In addition, the time required to obtain foreign
approval may differ from that required to obtain FDA approval and we may not obtain foreign regulatory approvals on a timely basis,
if at all. We may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products
in any foreign market.
Obtaining approval from regulatory authorities
may require successful clinical studies. Conducting successful clinical studies may require the enrollment of large numbers of
patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical trials and completion
of patient participation and follow-up depends on many factors, including the size of the patient population, the nature of the
trial protocol, the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects,
the availability of appropriate clinical trial investigators and support staff, the proximity of patients to clinical sites and
the ability of those patients to comply with the eligibility and exclusion criteria for participation in the clinical trial and
meet study compliance requirements.
Development of sufficient and appropriate clinical protocols
and data to demonstrate safety and efficacy are required and we may not adequately develop such protocols to support clearance
and approval. Further, the FDA may require us to submit data on a greater number of patients than we originally anticipated and/or
for a longer follow-up period or change the data collection requirements or data analysis applicable to our clinical trials. Delays
in patient enrollment or failure of patients or clinical investigators to continue to participate in a clinical trial may cause
an increase in costs and delays in the clearance or approval and attempted commercialization of our products or result in the
failure of the clinical trial. In addition, despite considerable time and expense invested in our clinical trials, the FDA may
not consider our data adequate to demonstrate safety and efficacy. Such increased costs and delays or failures could adversely
affect our business, operating results and prospects.
Even if our products are approved by
regulatory authorities, if we or our suppliers fail to comply with ongoing FDA or other foreign regulatory authority requirements,
or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from
the market.
Any product for which we obtain clearance
or approval, and the manufacturing processes, reporting requirements, post-approval clinical data and labeling and promotional
activities for such product, will be subject to continued regulatory review, oversight and periodic inspections by the FDA and
other domestic and foreign regulatory bodies. In particular, we and our suppliers are required to comply with QSR and Medical
Device Directive regulations, which may include ISO standards, for the manufacture of our products and other regulations which
cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage
and shipping of any product for which we obtain clearance or approval. Regulatory bodies enforce the QSR and ISO regulations through
inspections. The failure by us or one of our suppliers to comply with applicable statutes and regulations administered by the
FDA and other regulatory bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product
safety issues, could result in, among other things, warning letters, fines and civil penalties, delays in approving products,
withdrawal or suspension of the approval of products, product recalls, operating restrictions, or unanticipated expenditures to
address or defend regulatory actions. If any of these actions were to occur, it would harm our reputation and cause our product
sales and profitability to suffer and may prevent us from generating revenue. Furthermore, our key suppliers may not currently
be or may not continue to be in compliance with all applicable regulatory requirements which could result in our failure to produce
our products on a timely basis and in the required quantities, if at all.
Even if regulatory clearance or approval
of a product is granted, such clearance or approval may be subject to limitations on the intended uses for which the product may
be marketed and reduce our potential to successfully commercialize the product and generate revenue from the product. If the FDA
determines that our promotional materials, labeling, training or other marketing or educational activities constitute promotion
of an unapproved use, it could request that we cease or modify our training educational, labeling or promotional materials or
subject us to regulatory enforcement actions. It is also possible that other federal, state or foreign enforcement authorities
might take action if they consider our training educational, labeling or other promotional materials to constitute promotion of
an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting
false claims for reimbursement.
We are subject to extensive regulation
by the FDA. Our failure to meet strict regulatory requirements could require us to pay fines, incur other costs or even close
our facilities.
Our facilities and manufacturing techniques
generally must conform to standards that are established by the FDA and other government agencies, including those of European
and other foreign governments. These regulatory agencies may conduct periodic audits or inspections of our facilities or our processes
to monitor our compliance with applicable regulatory standards. If a regulatory agency finds that we have failed to comply with
the appropriate regulatory standards, it may impose fines on us, delay or withdraw pre-market clearances or other regulatory approvals
or, if such a regulatory agency determines that our non-compliance is severe, it may close our facilities. Any adverse action
by an applicable regulatory agency could impair our ability to produce our products in a cost-effective and timely manner in order
to meet our customers' demands. We may also be required to bear other costs or take other actions that may have a negative impact
on our future sales and our ability to generate profits.
Our products may in the future be subject
to product recalls that could harm our reputation, business and financial results.
The FDA and similar foreign governmental
authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects
in design or manufacture. In the case of the FDA, the authority to require a recall must be based on an FDA finding that there
is a reasonable probability that the device would cause serious injury or death. In addition, foreign governmental bodies have
the authority to require the recall of our products in the event of material deficiencies or defects in design or manufacture.
Manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found. A government-mandated
or voluntary recall by us or one of our distributors could occur as a result of component failures, manufacturing errors, design
or labeling defects or other deficiencies and issues. Recalls of any of our products would divert managerial and financial resources
and have an adverse effect on our financial condition and results of operations. The FDA requires that certain classifications
of recalls be reported to the FDA within 10 working days after the recall is initiated. Companies are required to maintain certain
records of recalls, even if they are not reportable to the FDA. We may initiate voluntary recalls involving our products in the
future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require
us to report those actions as recalls. A future recall announcement could harm our reputation with customers and negatively affect
our sales. In addition, the FDA could take enforcement action for failing to report the recalls when they were conducted. Any
recall or FDA requirement that we seek additional approvals or clearances could result in significant delays, fines, increased
costs associated with modification of a product, loss of revenue and potential operating restrictions imposed by the FDA.
If our products, or malfunctions of
our products, cause or contribute to a death or a serious injury, we will be subject to medical device reporting regulations,
which can result in voluntary corrective actions or agency enforcement actions.
Under the FDA medical device reporting
regulations, medical device manufacturers are required to report to the FDA information that a device has or may have caused or
contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to death or serious
injury if the malfunction of the device or one of our similar devices were to recur. All manufacturers placing medical devices
in the market in the European Union are legally bound to report any serious or potentially serious incidents involving devices
they produce or sell to the Competent Authority in whose jurisdiction the incident occurred. Were this to happen to us, the relevant
Competent Authority would file an initial report, and there would then be a further inspection or assessment if there are particular
issues. This would be carried out either by the Competent Authority or it could require that the Notified Body, carry out the
inspection or assessment.
Any such adverse event involving our products
could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection
or enforcement action. Adverse events involving our products have been reported to us in the past, and we cannot guarantee that
they will not occur in the future. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in
a lawsuit, will require the dedication of our time and capital, distract management from operating our business, and may harm
our reputation and financial results.
We are subject to complex and evolving
federal and state healthcare laws, including laws relating to fraud and abuse and health information privacy and security, and
could be subjected to governmental investigations into our compliance with such laws and substantial penalties if we are shown
to have failed to comply with such laws.
Although we do not provide healthcare
services, submit claims for third-party reimbursement, or receive payments directly from Medicare, Medicaid, or other third-party
payors for our products or the procedures in which our products are used, we are subject to healthcare fraud and abuse regulation
and enforcement by both the federal government and the states in which we conduct our business. These healthcare laws and regulations
include, for example:
|
·
|
the
federal Anti-kickback
Statute, which
prohibits, among
other things, persons
or entities from
soliciting, receiving,
offering or providing
remuneration, directly
or indirectly,
in return for or
to induce either
the referral of
an individual for,
or the purchase
order or recommendation
of, any item or
services for which
payment may be
made under a federal
healthcare program
such as the Medicare
and Medicaid programs;
|
|
·
|
HIPAA,
which established
federal crimes
for knowingly and
willfully executing
a scheme to defraud
any healthcare
benefit program
or making false
statements in connection
with the delivery
of or payment for
healthcare benefits,
items or services;
|
|
·
|
federal
false claims laws,
which prohibit,
among other things,
individuals or
entities from knowingly
presenting, or
causing to be presented,
claims for payment
from Medicare,
Medicaid, or other
third-party payors
that are false
or fraudulent,
and which may apply
to entities like
us to the extent
that our interactions
with customers
may affect their
billing or coding
practices; and
|
|
·
|
state
law equivalents
of each of the
above federal laws,
such as anti-kickback
and false claims
laws, which may
apply to items
or services reimbursed
by any third-party
payor, including
commercial insurers.
|
We have adopted policies and procedures
designed to comply with the various healthcare laws applicable to our business. However, because of the breadth of these laws
and regulations and the sometimes subjective nature of their application, it is possible that some of our business activities
could be subject to challenge under one or more of such laws. The risk of being found to have violated such laws is increased
by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions
are open to a variety of interpretations. In addition, in recent years, we believe that both federal and state regulators have
increased regulation, enforcement, inspections and governmental investigations of the medical device industry, which further increases
the risk that our business activities could be subject to challenge under certain laws. The Health Care Reform Law, among other
things, also amends the intent requirement of the federal anti-kickback and criminal healthcare fraud laws such that a person
or entity no longer needs to have actual knowledge of this statute or specific intent to violate it, which further expands the
breadth of the applicable laws. Furthermore, it is also possible that the government may assert that a claim including items or
services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes
of the false claims statutes.
As discussed in more detail in the risk
factor entitled “
We are involved in an ongoing governmental investigation, the existence and results of which may adversely
impact our business and results of operations,
” in October 2011 we received a subpoena issued by the OIG under the authority
of the federal healthcare fraud and false claims laws. We have cooperated with the government’s request and have reached
a tentative settlement with the U.S. Department of Justice as of December 24, 2012. We expect to have this settlement finalized
in the first half of 2013.
If our past or present operations, or
those of our independent sales agents and distributors, are found to be in violation of any federal healthcare fraud and false
claims laws, or any other applicable governmental regulations, we may be subject to penalties, including civil and criminal penalties,
damages, fines, exclusion from federal healthcare programs and/or the curtailment or restructuring of our operations.
If the healthcare providers or entities
with whom we do business are found to be non-compliant with applicable laws, they may be subject to sanctions, which could also
have a negative impact on us. Any action against us for violation of these laws, even if we successfully defend against them,
could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business.
The Health Care Reform Law imposes new
reporting and disclosure requirements on device manufacturers for any “transfer of value” made or distributed to prescribers
and other healthcare providers, effective March 30, 2013. Such information will be made publicly available in a searchable
format beginning September 30, 2013. In addition, device manufacturers will also be required to report and disclose any investment
interests held by physicians and their immediate family members during the preceding calendar year. Failure to submit required
information may result in civil monetary penalties of up to an aggregate of $150,000 per year (and up to an aggregate of $1 million
per year for “knowing failures”), for all payments, transfers of value or ownership or investment interests not reported
in an annual submission.
In addition, there has been a recent trend
of increased federal and state regulation of payments made to physicians for marketing. Some states, such as California, Massachusetts
and Vermont, mandate implementation of corporate compliance programs, along with the tracking and reporting of gifts, compensation,
and other remuneration to physicians. The shifting commercial compliance environment and the need to build and maintain robust
and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases
the possibility that a healthcare company may run afoul of one or more of the requirements.
We are involved in an ongoing governmental
investigation, the existence and results of which may adversely impact our business and results of operations.
In October 2011, we received a subpoena
issued by the OIG, under the authority of the federal healthcare fraud and false claims laws. The subpoena sought documents for
the period January 1, 2008 through October 6, 2011. We have cooperated with the government’s request.
On
December 24, 2012 we reached a tentative agreement in principle with the U.S. Department of Justice related to the subpoena issued
in October 2011. We tentatively agreed with the staff of the Department of Justice to settle its federal investigation for $6
million, subject to completion and approval of written settlement agreements with the Department of Justice and the OIG, which
are expected to be finalized in the first half of 2013. We admit no wrongdoing as part of the settlement.
We are also unable
to predict what impact, if any, the outcome of the matters raised by the OIG will have on the willingness of surgeons to accept
our products, our ability to hire or retain sales representatives and other employees, potential future reimbursement decisions
by payors or other significant aspects of our business.
The use, misuse or off-label use of
our products may harm our image in the marketplace or result in injuries that lead to product liability suits, which could be
costly to our business or result in FDA sanctions if we are deemed to have engaged in such promotion.
Our currently marketed products have been
cleared by the FDA’s 510(k) clearance process (or were exempt from the 510(k) process) for use under specific circumstances
for the treatment of certain lumbar spine conditions. We cannot, however, prevent a physician from using our products or procedure
outside of those indications cleared for use, known as off-label use. There may be increased risk of injury if physicians attempt
to use our products off-label. We train our sales force not to promote our products for off-label uses. Furthermore, the use of
our products for indications other than those indications for which our products have been cleared by the FDA may not effectively
treat such conditions, which could harm our reputation in the marketplace among physicians and patients. Physicians may also misuse
our products or use improper techniques, potentially leading to injury and an increased risk of product liability. If our products
are misused or used with improper technique, we may become subject to costly litigation by our customers or their patients. Product
liability claims could divert management’s attention from our core business, be expensive to defend and result in sizable
damage awards against us that may not be covered by insurance. If we are deemed by the FDA to have engaged in the promotion of
any of our products for off-label use, it could request that we modify our training or promotional materials or we could be subject
to FDA enforcement action, including significant fines and penalties, and the imposition of these sanctions could also affect
our reputation and position within the industry. It is also possible that other federal, state or foreign enforcement authorities
might take action if they consider our promotional or training materials to constitute promotion of an unapproved use, which could
result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement.
Any of these events could harm our business and results of operations and cause our stock price to decline.
Risks Related to Our Intellectual Property
Our ability to protect our intellectual
property and proprietary technology through patents and other means is uncertain.
The success of our business depends significantly
on our ability to protect our proprietary rights to the procedures created with, and the technologies used in, our products. We
rely on patent protection, as well as a combination of copyright, trade secret and trademark laws, and nondisclosure, confidentiality
and other contractual restrictions to protect our proprietary technology. However, these legal means afford only limited protection
and may not adequately protect our rights or permit us to gain or keep any competitive advantage. For example, our pending United
States and foreign patent applications may not be approved, may not result in patents in a form that will be advantageous to us,
or may result in patents that may be successfully challenged by others and invalidated in the future. In addition, our pending
patent applications include claims to material aspects of our products and procedures that are not currently protected by issued
patents. Both the patent application process and the process of managing patent disputes can be time consuming and expensive.
The patents we own may not be of sufficient scope or strength to provide us with any meaningful protection or commercial advantage,
and competitors may be able to design around our patents or develop products that provide outcomes comparable to ours. Although
we have taken steps to protect our intellectual property and proprietary technology, including entering into confidentiality agreements
and intellectual property assignment agreements with our officers, employees, consultants and advisors, such agreements may not
be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of
unauthorized use or disclosure or other breaches of such agreements. Furthermore, the laws of some foreign countries do not protect
our intellectual property rights to the same extent as do the laws of the United States.
We rely on our trademarks, trade names,
and brand names to distinguish our products from the products of our competitors, and have registered or applied to register many
of these trademarks. However, our trademark applications may not be approved. Third parties may also oppose our trademark applications,
or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced
to rebrand our products, which could result in loss of brand recognition, and could require us to devote resources to advertising
and marketing new brands. Further, our competitors may infringe our trademarks, or we may not have adequate resources to enforce
our trademarks.
Any lawsuit, whether initiated by us
to enforce our intellectual property rights or by a third party against us alleging infringement, may cause us to expend significant
financial and other resources, and may divert our attention from our business and adversely affect our business, operating results
and prospects.
The medical
device industry is characterized by the existence of a large number of patents and frequent litigation based on allegations of
patent infringement.
While we intend to defend against any threats
to our intellectual property, intellectual property
litigation can involve complex factual
and legal questions and its outcome is uncertain.
There can be
no assurance that litigation will adequately protect our patents or that our competitors will not independently develop products
or solutions that are equivalent or superior to ours. Because of the importance of our patent portfolio and unpatented proprietary
technology to our business, we may lose market share to our competitors if we fail to protect our patent rights.
Our success will also depend in part on
our not infringing patents issued to others, including our competitors and potential competitors. If our products are found to
infringe the patents of others, our development, manufacture, and sale of such products could be severely restricted or prohibited.
In addition, any
claim relating to infringement of patents that is successfully asserted against
us may require us to pay substantial damages. Even if we were to prevail, any litigation could be costly and time-consuming and
would divert the attention of our management and key personnel from our business operations.
Additionally, if we infringe, or are claimed
to infringe, a third party’s intellectual property, we may be forced
to obtain licenses
to patents or proprietary rights of others in order to continue to commercialize our products. However, even if we, our strategic
partners or our licensees are able to obtain rights to the third party’s intellectual property, these rights may be non-exclusive,
thereby giving our competitors access to the same intellectual property. Also, there is the possibility that we may not be able
to obtain any licenses required under any patents or proprietary rights of third parties on acceptable terms, or at all. Ultimately,
we may be unable to commercialize some of our potential products or may have to cease some of our business operations as a result
of patent infringement claims, which could severely harm our business.
Risks Related to the Merger and the
Private Placement Transaction
We may not realize all of the anticipated
benefits of the Merger.
The success of the Merger will depend,
in part, on our ability to realize the anticipated growth opportunities and synergies from combining the businesses of our company
and Baxano. The integration of the businesses is a complex, time-consuming, and expensive process that, without proper planning
and effective and timely implementation, could significantly disrupt our operations following closing. Our ability to realize
the benefits of the Merger, and the timing of this realization, depend upon a number of factors, including:
|
·
|
obtaining and maintaining patent rights relating to Baxano’s products;
|
|
·
|
effectively consolidating our sales, marketing, research and development and other operations;
|
|
·
|
retaining and attracting key employees;
|
|
·
|
integrating and harmonizing financial reporting and information technology systems;
|
|
·
|
consolidating corporate and administrative functions;
|
|
·
|
preserving our and Baxano’s important business relationships;
|
|
·
|
minimizing the diversion of management’s attention from ongoing business concerns; and
|
|
·
|
establishing and maintaining appropriate internal controls over financial reporting and disclosure controls and procedures.
|
In addition, the actual integration may
result in additional and unforeseen expenses, and the anticipated benefits of the integration plan may not be realized. Actual
cost synergies, if achieved at all, may be lower than we expect and may take longer to achieve than anticipated. If we are not
able to adequately address these challenges, we may be unable to successfully integrate our operations with Baxano’s operations,
or to realize the anticipated benefits of the integration following the closing. The anticipated benefits and synergies assume
a successful integration and are based on projections, which are inherently uncertain, and other assumptions. Even if integration
is successful, anticipated benefits and synergies may not be achieved. An inability to realize the full extent of, or any of,
the anticipated benefits of the Merger, as well as any delays encountered in the integration process, could have an adverse effect
on our business and results of operations, which may affect the value of the shares of our common stock after the closing.
The Merger and the Private Placement Transaction are subject
to conditions to closing that could result in such transactions being delayed or not consummated, which could negatively impact
our stock price and future business and operations.
The Merger and the Private Placement Transaction
are subject to conditions to closing as set forth in the Merger Agreement and the Securities Purchase Agreement, including obtaining
the requisite approval of our stockholders of the issuance of shares of our common stock pursuant to the Merger Agreement and
the Securities Purchase Agreement. In addition, it is a condition to the closing of the Merger or the Private Placement Transaction
that both transactions close concurrently. If any of the conditions to the closing of the Merger and the Private Placement Transaction
are not satisfied or, where permissible, not waived, neither the Merger nor the Private Placement Transaction will be consummated.
Failure to consummate the Merger and the Private Placement Transaction could negatively impact our stock price, future business
and operations, and financial condition. In addition, any delay in the consummation of the Merger and the Private Placement Transaction,
or any uncertainty about the consummation of the Merger and the Private Placement Transaction, may adversely affect our future
business, growth, revenue, and results of operations.
If the former stockholders of Baxano
and/or the Investors sell a substantial amount of our common stock received in the Merger and the Private Placement Transaction,
they could cause our common stock price to decline.
We have agreed to file a registration statement
on Form S-1 or Form S-3 to register the resale of the shares of our common stock to be issued to the stockholders of Baxano in
the Merger and to the investors in the Private Placement Transaction under the federal securities laws. Pursuant to the Securities
Purchase Agreement, the investors in the Private Placement Transaction and all other holders of shares received pursuant to the
Merger Agreement agreed not to sell, transfer, or otherwise dispose of the shares of the Company’s common stock issued at
the closing of the Merger and the Private Placement Transaction from the period commencing on such closing and expiring on the
effective date of such registration statement, subject to certain exceptions. Once the registration statement is declared effective,
all of the shares of common stock issued pursuant to the Merger Agreement and the Securities Purchase Agreement will be available
for resale in the public market. The sale of a substantial number of shares of our common stock by former Baxano stockholders,
the investors, or our other stockholders within a short period of time could cause our stock price to decrease and make it more
difficult for us to raise funds through future offerings of common stock.
We have incurred and will incur significant
costs in connection with the Merger and the Private Placement Transaction, whether or not we complete them.
We have incurred significant costs related
to the Merger and the Private Placement Transaction and we expect to incur significant additional costs. These costs include our
financial advisory, legal, and accounting fees, expenses, and other charges. In addition, the Merger Agreement grants certain
termination rights to Baxano under which we would be required to pay Baxano a termination fee equal to $2,000,000 and to reimburse
Baxano for its expenses incurred relating to the transactions contemplated by the Merger Agreement, up to a cap of $750,000. We
may also incur additional unanticipated costs for any of a number of reasons. Such costs will reduce the assets that we would
have if the Merger and the Private Placement Transaction are not consummated, or that we would have to operate our business after
the Merger and the Private Placement Transaction.
After the completion of the Merger,
the surviving corporation, which will be a wholly-owned subsidiary of the Company, will possess not only all of the assets, but
also all of the liabilities of Baxano. Discovery of previously undisclosed or unknown liabilities could have an adverse effect
on our business, operating results, and financial condition.
Acquisitions involve risks, including
inaccurate assessment of undisclosed, contingent, or other liabilities or problems. After the completion of the Merger, the surviving
corporation, which will be a wholly-owned subsidiary of the Company, will possess not only all of the assets, but also all of
the liabilities of Baxano. Although we conducted a due diligence investigation of Baxano and its known and potential liabilities
and obligations, it is possible that undisclosed, contingent, or other liabilities or problems may arise after the completion
of the Merger, which could have an adverse effect on our business, operating results, and financial condition. The amount of such
liabilities may be in excess of the value of the Merger consideration that will be placed into an escrow fund for 12 months following
the closing of the Merger to secure our rights to indemnification under the Merger Agreement, or we may not be entitled to indemnification
for such liabilities under the Merger Agreement, or such liabilities may not be uncovered until after the escrow fund has been
released.
Risks Related to Our Common Stock
Our directors,
officers and principal stockholders have significant voting power and may take actions that may not be in the best interests of
our other stockholders.
As of December 31, 2012, our officers,
directors and principal stockholders, collectively held approximately 49.0% of our outstanding common stock. These stockholders,
if they act together, could potentially exercise their significant voting power and influence the management and affairs of our
company and most matters requiring stockholder approval, including the election of directors and approval of significant corporate
transactions. This concentration of ownership may not be in the best interests of our other stockholders.
We may be unable to utilize our net
operating loss carryforwards to reduce our income taxes.
As of December 31, 2012, we have federal
net operating loss, or NOL, carryforwards of approximately $105.6 million. Our ability to utilize NOL carryforwards to reduce
future taxable income may be limited under Section 382 of the Internal Revenue Code of 1986 as amended, or the Code, if an
“ownership change” in our company occurs during a rolling three-year period. An ownership change could result from,
among other things, the offering of stock by us, the purchase or sale of our stock by 5% stockholders, as defined in the
Treasury regulations, or the issuance or exercise of rights to acquire our stock. If such ownership changes by 5% stockholders
result in aggregate increases that exceed 50 percentage points during the rolling three-year period, then Section 382 imposes
an annual limitation on the amount of our taxable income that may be offset by our NOL carryforwards at the time of ownership
change. While we do not believe the proposed Merger and Private Placement Transaction will, by itself, constitute an ownership
change, we have not yet analyzed whether an ownership change would result if the Merger and Private Placement Transaction are
aggregated with our issuances of common stock during the prior three-year period. It is also possible that future transactions
could be aggregated with the Merger and Private Placement Transaction to result in an ownership change. If an ownership change
were to occur, we may be unable to use a significant portion of our NOL carryforwards to offset taxable income.
The price of our common stock has been, and may continue
to be, volatile and our stockholders may not be able to resell shares of our common stock at or above the price paid for such
shares.
The
price for shares of our common stock on the NASDAQ Global Market has exhibited high levels of volatility with significant price
fluctuations, which makes our common stock unsuitable for many investors. For example, for the three years ended December 31,
2012, the closing price of our common stock ranged from a high of $5.35 per share to a low of $1.50 per share. At times, the fluctuations
in the price of our common stock may have been unrelated to our operating performance. These broad fluctuations may negatively
impact the market price
of shares of our common stock.
Trading in our stock has historically
been limited, so investors may not be able to sell as much stock as they want at prevailing prices.
The average daily trading volume in our
common stock for the year ended December 31, 2012 was approximately 64,000 shares. If limited trading in our stock continues,
it may be difficult for investors to sell their shares in the public market at any given time at prevailing prices. Moreover,
the market price for shares of our common stock may be made more volatile because of the relatively low volume of trading in our
common stock. When trading volume is low, significant price movement can be caused by the trading in a relatively small number
of shares. Volatility in our common stock could cause stockholders to incur substantial losses.
Our amended and restated certificate
of incorporation, amended and restated bylaws and Delaware law contain provisions that could have the effect of deterring or delaying
changes in incumbent management, proxy contests or changes in control.
Anti-takeover provisions of our amended
and restated certificate of incorporation, amended and restated bylaws and Delaware law may have the effect of deterring or delaying
attempts by our stockholders to remove or replace management, engage in proxy contests and effect changes in control. The provisions
of our charter documents include:
|
·
|
a
classified board
so that only one
of the three classes
of directors on
our Board of Directors
is elected each
year;
|
|
·
|
procedures
for advance notification
of stockholder
director nominations
and proposals;
|
|
·
|
a
prohibition on
stockholders being
able to call a
special meeting
of stockholders;
|
|
·
|
the
ability of our
Board of Directors
to amend our bylaws
without stockholder
approval;
|
|
·
|
a
supermajority stockholder
vote requirement
for amending certain
provisions of our
amended and restated
certificate of
incorporation and
our amended and
restated bylaws;
and
|
|
·
|
the
ability of our
Board of Directors
to issue up to
5,000,000 shares
of preferred stock
without stockholder
approval upon the
terms and conditions
and with the rights,
privileges and
preferences as
our Board of Directors
may determine.
|
In addition, as a Delaware corporation,
we are subject to Delaware law, including Section 203 of the Delaware General Corporation Law, or DGCL. In general, Section 203
prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three
years following the date that the stockholder became an interested stockholder unless certain specific requirements are met as
set forth in Section 203. These provisions, alone or together, could have the effect of deterring or delaying changes in incumbent
management, proxy contests or changes in control.